Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
37.5 /100
Rank 67 out of 131 Industries -
Advance/Decline
94/231
-
No. of Companies325
-
Avg. Market Cap15,306
-
Price to Earning Ratio7.54
-
Price to Earning Growth Ratio0.96
-
Price to Book Ratio21.29
-
Return on Equity12.31
-
Return on Capital Employed-
-
Return on Assets7.31
-
Dividend yield 1 year %0.70 %
-
Net Profit Growth Annual YoY %-66.73 %
-
Net Profit Growth Qtr YoY %-806.38 %
-
Net Profit Growth Qtr QoQ %-285.03 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
450,072.8
|
254.7
|
L
 0.1%
H
252.9
256.2
|
L
 2.7%
H
243.1
261.0
|
L
 17.7%
H
221.9
261.6
|
L
 22.3%
H
190.8
261.6
|
L
 34.6%
H
184.6
261.6
|
L
 85.0%
H
135.9
261.6
|
L
 120.7%
H
105.6
261.6
|
L
 302.3%
H
55.1
261.6
|
| Adc Therapeutics SA |
|
165.3
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 0.8%
H
1.2
1.5
|
L
 19.3%
H
1
1.5
|
L
 -69.6%
H
0.8
4.3
|
L
 -57.1%
H
0.8
5.0
|
L
 -13.3%
H
0.4
6.0
|
L
 -94.2%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,661.7
|
17.7
|
L
 -0.7%
H
17.7
18.2
|
L
 4.2%
H
16.6
18.4
|
L
 9.4%
H
15.9
18.4
|
L
 27.5%
H
11.8
18.4
|
L
 122.5%
H
7.7
18.4
|
L
 450.6%
H
3.0
18.4
|
L
 310.4%
H
1.2
18.4
|
L
 -41.3%
H
1.2
31.9
|
| Annovis Bio Inc |
|
71.5
|
1.7
|
L
 -3.5%
H
1.7
1.7
|
L
 -9.7%
H
1.7
1.9
|
L
 -4%
H
1.6
2.2
|
L
 -10.2%
H
1.6
2.5
|
L
 -36.6%
H
1.5
5.5
|
L
 -87.7%
H
1.1
22.5
|
L
 -98.3%
H
1.1
132
|
L
H
1.1
132
|
| Bristol-Myers Squibb |
|
124,178.4
|
60.8
|
L
 0.1%
H
60.7
61.4
|
L
 5.6%
H
56.8
62.3
|
L
 12.6%
H
54
62.3
|
L
 1.1%
H
53.4
62.3
|
L
 28.4%
H
42.5
62.9
|
L
 -2.0%
H
39.4
65.4
|
L
 -8.4%
H
39.4
81.4
|
L
 -19.4%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
391.1
|
7.6
|
L
 -0.7%
H
7.5
7.7
|
L
 -5.8%
H
7.4
8.2
|
L
 -5.3%
H
7.4
8.6
|
L
 -14.0%
H
7.4
9.7
|
L
 9.4%
H
5.6
14.1
|
L
 5.7%
H
1.4
15.1
|
L
 -88.1%
H
1.4
68.0
|
L
 -73.5%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
101,922.4
|
50.9
|
L
 -1.7%
H
50.8
51.7
|
L
 -3.6%
H
50.8
52.9
|
L
 0.4%
H
50.6
54.3
|
L
 -12.8%
H
48.6
58.3
|
L
 40.2%
H
36.2
61.7
|
L
 44.6%
H
31.7
61.7
|
L
 27.2%
H
28.5
61.7
|
L
 14.4%
H
28.5
61.7
|
| Johnson & Johnson |
|
605,222.5
|
251.4
|
L
 -0.6%
H
250.5
254.2
|
L
 -2.2%
H
246.1
259.5
|
L
 10.1%
H
227.5
269.4
|
L
 7.4%
H
220.4
269.4
|
L
 53.6%
H
162.8
269.4
|
L
 58.4%
H
140.7
269.4
|
L
 50.7%
H
140.7
269.4
|
L
 100.7%
H
109.2
269.4
|
| Eli Lilly |
|
1,049,972.0
|
1,177.4
|
L
 -0.1%
H
1165.5
1187.1
|
L
 -0.9%
H
1134.4
1196.3
|
L
 7.2%
H
1079.2
1249.5
|
L
 27.0%
H
850.5
1249.5
|
L
 52.6%
H
623.8
1249.5
|
L
 159.6%
H
446.6
1249.5
|
L
 402.9%
H
220.2
1249.5
|
L
 1372.4%
H
64.2
1249.5
|
| Merck & Company |
|
313,173.7
|
126.8
|
L
 -0.6%
H
126.0
127.9
|
L
 2.6%
H
120.2
131.7
|
L
 11.4%
H
113
131.7
|
L
 6.5%
H
107.9
131.7
|
L
 58.6%
H
76.7
131.7
|
L
 19.7%
H
73.3
134.6
|
L
 64.6%
H
70.9
134.6
|
L
 126.5%
H
50.4
134.6
|
| Novo Nordisk (ADR) |
|
221,191.5
|
50
|
L
 -0.6%
H
49.6
50.5
|
L
 1.1%
H
48.3
51.8
|
L
 15.8%
H
43.9
51.8
|
L
 23.4%
H
38.0
51.8
|
L
 -22.3%
H
35.1
71.8
|
L
 -37.6%
H
35.1
148.2
|
L
 13.2%
H
35.1
148.2
|
L
 82.1%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
290,487.9
|
152.2
|
L
 -1.0%
H
151.9
153.5
|
L
 -1.2%
H
149.7
155.3
|
L
 3.5%
H
146.6
160.6
|
L
 0.2%
H
142.3
160.6
|
L
 33.3%
H
112.3
170.5
|
L
 47.5%
H
92.2
170.5
|
L
 68.0%
H
74.1
170.5
|
L
 111.2%
H
59.2
170.5
|
| Organon & Co. |
|
3,550.5
|
13.5
|
L
H
13.5
13.5
|
L
H
13.5
13.5
|
L
 0.7%
H
13.4
13.6
|
L
 38.5%
H
8.5
13.6
|
L
 42.9%
H
5.7
13.6
|
L
 -35.0%
H
5.7
24.1
|
L
 -53.6%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,362.5
|
49.9
|
L
 -0.1%
H
48.7
50.0
|
L
 2.0%
H
47.0
51.6
|
L
 6.2%
H
45.2
51.6
|
L
 -14.2%
H
42.6
60.3
|
L
 -34.2%
H
42.6
77.5
|
L
 -17.6%
H
42.6
90.0
|
L
 -4.0%
H
42.6
90.0
|
L
 -8.5%
H
26.3
90.0
|
| Pfizer |
|
142,201.1
|
25.0
|
L
 -0.4%
H
24.9
25.2
|
L
 3.2%
H
24.1
25.7
|
L
 -1.0%
H
23.6
25.7
|
L
 -9.5%
H
23.6
27.8
|
L
 2.0%
H
23.1
28.7
|
L
 -31.5%
H
20.9
37.8
|
L
 -37.9%
H
20.9
61.7
|
L
 -28.1%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,451.5
|
10.5
|
L
 -2.2%
H
10.4
10.8
|
L
 2.6%
H
9.8
11.4
|
L
 2.3%
H
9.4
11.6
|
L
 -11.1%
H
9.4
12.6
|
L
 -61.1%
H
9.2
28.4
|
L
 -69.4%
H
9.2
40.3
|
L
 -76.9%
H
9.2
50.9
|
L
 -88.7%
H
9.2
99.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,450.5
|
12.6
|
L
 -0.4%
H
12.5
12.7
|
L
 -4.9%
H
12.5
13.3
|
L
 -5.6%
H
12.5
15.7
|
L
 -5.6%
H
12.2
15.7
|
L
 -13.3%
H
12.2
15.7
|
L
 -0.9%
H
12.2
74.9
|
L
 -13.3%
H
9.6
74.9
|
L
 17.3%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
54,449.2
|
17.1
|
L
 -0.6%
H
17.0
17.2
|
L
 3.0%
H
16.2
17.2
|
L
 9.1%
H
15.4
17.2
|
L
 -4.3%
H
14.8
17.7
|
L
 18.2%
H
13.0
18.9
|
L
 10.4%
H
12.6
18.9
|
L
 1.0%
H
12.3
18.9
|
L
 -18.7%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
36,737.7
|
31.6
|
L
 -1.5%
H
31.5
32.3
|
L
 -4.3%
H
31.3
32.8
|
L
 0.2%
H
31.3
35.5
|
L
 -2.6%
H
30.0
37.0
|
L
 96.5%
H
15.0
37.3
|
L
 268.6%
H
8.1
37.3
|
L
 276.5%
H
6.8
37.3
|
L
 -41.1%
H
6.1
55.8
|
| Zoetis (Class A) |
|
31,727.2
|
75.7
|
L
 -1.2%
H
74.7
75.8
|
L
 0.2%
H
73.4
78.1
|
L
 -3.9%
H
71.5
79.9
|
L
 -37.9%
H
71.5
123.3
|
L
 -49.1%
H
71.5
160.5
|
L
 -55.7%
H
71.5
201.9
|
L
 -61.7%
H
71.5
249.3
|
L
 53.3%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,244.9
|
14.9
|
L
 -3.4%
H
14.9
15.8
|
L
 -4.1%
H
13.6
15.8
|
L
 9.9%
H
13.6
17.3
|
L
 35.8%
H
8.2
17.3
|
L
 6.1%
H
7.5
18.6
|
L
 -41.6%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
44,214.1
|
10.0
|
L
 -0.6%
H
10.0
10.1
|
L
 2.9%
H
9.6
10.2
|
L
 12.1%
H
8.8
10.2
|
L
 3.0%
H
8.7
10.2
|
L
 4.6%
H
8.7
11.3
|
L
 15.8%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Abeona Therapeutics Inc |
|
374.5
|
6.6
|
L
 -6.1%
H
6.5
7.1
|
L
 -5.9%
H
6.5
7.4
|
L
 13.9%
H
5.5
7.4
|
L
 19.5%
H
5.1
7.4
|
L
 -0.3%
H
4
7.5
|
L
 73.4%
H
2.9
9.0
|
L
 -78.6%
H
2.2
38.5
|
L
 -89.1%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
5,693.5
|
94.4
|
L
 1.8%
H
93.1
96.3
|
L
 8.8%
H
80.7
96.3
|
L
 30.5%
H
79
97.8
|
L
 37.0%
H
53.6
97.8
|
L
 549.2%
H
12.8
97.8
|
L
 285.6%
H
2.2
97.8
|
L
 173.1%
H
2.2
97.8
|
L
 -85.3%
H
2.2
693.4
|
| Acumen Pharma Inc |
|
156.7
|
2.2
|
L
 -3.6%
H
2.2
2.3
|
L
 -17.5%
H
2.1
2.8
|
L
 -4.0%
H
2.1
2.8
|
L
 -23.1%
H
2.1
3.0
|
L
 44.7%
H
1.2
3.6
|
L
 -70.7%
H
0.9
7.7
|
L
 -88.6%
H
0.9
19.7
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
883.0
|
4.5
|
L
 -2.0%
H
4.5
4.6
|
L
 -6.9%
H
4.5
4.9
|
L
 -1.8%
H
4.3
5.4
|
L
 -5.3%
H
4.0
5.4
|
L
 42.8%
H
3.1
5.4
|
L
 97.8%
H
1.7
5.4
|
L
 64.9%
H
1.7
6.5
|
L
 9.8%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
32.2
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -17.9%
H
1.2
1.5
|
L
 -8.2%
H
1.2
2.2
|
L
 -6.1%
H
1
2.2
|
L
 -63.0%
H
0.9
3.6
|
L
 -70.5%
H
0.4
6.9
|
L
 -97.5%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,344.3
|
25.4
|
L
 -0.9%
H
25.0
26.2
|
L
 -3.2%
H
25.0
26.2
|
L
 17.4%
H
21.6
27.3
|
L
 14.4%
H
20.3
27.3
|
L
 12.5%
H
19.7
28.4
|
L
 -20.5%
H
13.4
32.6
|
L
 9.3%
H
12.2
33.9
|
L
 -22.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
73.9
|
7.9
|
L
 -2.7%
H
7.9
8.1
|
L
 -10.5%
H
7.9
9.2
|
L
 -2.5%
H
7.9
9.4
|
L
 -3.9%
H
7.0
9.5
|
L
 -35.0%
H
6.0
17.4
|
L
 -84.7%
H
6.0
60.3
|
L
 -93.8%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
627.2
|
6.1
|
L
 -2.6%
H
6.1
6.4
|
L
H
5.8
6.4
|
L
 26.0%
H
4.9
7.1
|
L
 19.8%
H
3.9
7.1
|
L
 128.0%
H
2.4
7.1
|
L
 15.7%
H
1.8
7.1
|
L
 -18.1%
H
1.8
10.3
|
L
 -99.7%
H
1.8
2178
|
| AC Immune SA |
|
222.9
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 -8.4%
H
2.1
2.5
|
L
 -8.8%
H
2.1
2.7
|
L
 -27.2%
H
2.1
3.2
|
L
 5.8%
H
2.0
4
|
L
 -27.2%
H
1.4
5.1
|
L
 -70.2%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
773.7
|
5.5
|
L
 -2.5%
H
5.5
5.9
|
L
 -0.7%
H
5.2
5.9
|
L
 23.1%
H
4.5
5.9
|
L
 30.4%
H
4.1
5.9
|
L
 244.1%
H
1.5
5.9
|
L
 -46.9%
H
0.6
10.8
|
L
 -61.0%
H
0.6
20.0
|
L
 -72.6%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
73.6
|
1.7
|
L
 -1.7%
H
1.7
1.8
|
L
 -12.2%
H
1.7
2.2
|
L
 9.6%
H
1.6
2.2
|
L
 -3.4%
H
1.4
2.2
|
L
 27.4%
H
1.2
3.6
|
L
 -86.9%
H
1.1
13.4
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Grace Therapeutics Inc |
|
39.7
|
2.4
|
L
 -1.2%
H
2.4
2.5
|
L
 -0.4%
H
2.3
2.5
|
L
 2.5%
H
2.1
2.6
|
L
 -47.0%
H
1.8
5.1
|
L
 -27.4%
H
1.8
5.2
|
L
 -3.9%
H
1.7
5.2
|
L
 -89.3%
H
1.7
27.1
|
L
 -96.4%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.6
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 2%
H
1.5
1.9
|
L
 -0.7%
H
1.3
1.9
|
L
 -35.7%
H
1.3
2.4
|
L
 -83%
H
1.3
10.0
|
L
 -96.5%
H
1.3
176.4
|
L
 -98.7%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
5.9
|
2.7
|
L
 -3.6%
H
2.6
2.8
|
L
 -2.9%
H
2.6
2.9
|
L
 3.9%
H
2.3
3.0
|
L
 65.6%
H
1.3
5.2
|
L
 -76.1%
H
1.3
18.9
|
L
 -98.5%
H
1.3
221.9
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Agios Pharma Inc |
|
2,377.7
|
40.0
|
L
 0.9%
H
39.7
40.5
|
L
 -3.0%
H
38.0
41.1
|
L
 17.0%
H
34.3
44.1
|
L
 13.8%
H
24.3
44.1
|
L
 -0.1%
H
22.2
46
|
L
 51.0%
H
19.8
62.6
|
L
 -29.0%
H
16.8
62.6
|
L
 -0.2%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
354.1
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -5.7%
H
1.3
1.4
|
L
 23.4%
H
1.0
1.5
|
L
 -5.7%
H
0.8
1.5
|
L
 -65.8%
H
0.8
4.0
|
L
 6.5%
H
0.8
4.1
|
L
 -54.2%
H
0.2
4.1
|
L
 -83.9%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
33.7
|
5.5
|
L
 -5.1%
H
5.3
5.7
|
L
 -17.7%
H
5.3
6.6
|
L
 3.2%
H
5.3
7.1
|
L
 -18.4%
H
4.8
7.1
|
L
 -40.5%
H
4.8
13.7
|
L
 -78.2%
H
3.8
46.3
|
L
 -98.6%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,743.8
|
52.5
|
L
 -0.5%
H
52.4
53.2
|
L
 1%
H
50.5
53.5
|
L
 16.6%
H
45
55.7
|
L
 51.9%
H
32.8
55.7
|
L
 79.5%
H
25.2
55.7
|
L
 65.3%
H
22.0
55.7
|
L
 124.5%
H
21.2
55.7
|
L
 11.0%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
18.5
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
H
1.1
1.2
|
L
 -18.9%
H
1.0
1.5
|
L
 -5.7%
H
1.0
1.8
|
L
 16%
H
0.8
2.1
|
L
 -98.1%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
36,331.4
|
272.1
|
L
 1.7%
H
266.3
272.2
|
L
 -8.9%
H
266.3
298.8
|
L
 -2.2%
H
266.3
380
|
L
 -12.1%
H
266.3
380
|
L
 -15.1%
H
266.3
495.6
|
L
 32.5%
H
142.0
495.6
|
L
 55.2%
H
117.6
495.6
|
L
 325.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
71.9
|
0.8
|
L
 -2.3%
H
0.8
0.9
|
L
 -14.3%
H
0.8
1
|
L
 -8.7%
H
0.8
1.1
|
L
 -52.3%
H
0.8
2.1
|
L
 -40.9%
H
0.8
2.2
|
L
 -53.8%
H
0.8
7.4
|
L
 -96.1%
H
0.8
25.4
|
L
H
0.8
309.6
|
| Alzamend Neuro Inc |
|
4.6
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 1.7%
H
1.1
1.3
|
L
 -1.6%
H
1.1
1.4
|
L
 7.1%
H
1
1.4
|
L
 -63.4%
H
0.8
3.4
|
L
 -99.8%
H
0.8
715.5
|
L
 -100.0%
H
0.8
11178
|
L
H
0.8
45292.5
|
| Amylyx Pharma Inc |
|
1,969.1
|
17.7
|
L
 -0.2%
H
17.7
18.5
|
L
 -0.3%
H
16.5
18.5
|
L
 13.0%
H
15.7
19.2
|
L
 -3.5%
H
12.4
19.2
|
L
 112.4%
H
7.5
19.2
|
L
 -20.0%
H
1.6
25.5
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
866.9
|
19.7
|
L
 -0.4%
H
19.6
19.9
|
L
 5.0%
H
18.4
20.4
|
L
 4.5%
H
18.2
22
|
L
 -14.1%
H
16.6
24.3
|
L
 -4.7%
H
16.6
31.3
|
L
 -68.5%
H
16.6
67.7
|
L
 -1.8%
H
16.6
67.7
|
L
 15.2%
H
12.1
67.7
|
| Annexon Inc |
|
932.3
|
5.7
|
L
 -1.9%
H
5.7
5.9
|
L
 -1.9%
H
5.4
6.6
|
L
 16.1%
H
4.9
6.6
|
L
 -13%
H
4.5
6.6
|
L
 145.3%
H
2.0
7.2
|
L
 53.8%
H
1.3
8.4
|
L
 -75.0%
H
1.3
23.8
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
178.3
|
5.0
|
L
 5.8%
H
4.7
5.2
|
L
 10%
H
4.4
5.2
|
L
 -1%
H
4.1
5.5
|
L
 37.1%
H
3.5
5.5
|
L
 350%
H
1
6.9
|
L
 -37.5%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Aprea Therapeutics Inc |
|
8.5
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -6.8%
H
0.6
0.8
|
L
 -4.2%
H
0.6
0.9
|
L
 -31%
H
0.6
1.1
|
L
 -58.4%
H
0.6
2.2
|
L
 -79.8%
H
0.6
8.9
|
L
 -99.3%
H
0.6
117.8
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
501.9
|
4
|
L
 -2.9%
H
4.0
4.2
|
L
 -2.9%
H
3.8
4.2
|
L
 -15.1%
H
3.8
5.2
|
L
 -7.4%
H
3.8
5.2
|
L
 -4.8%
H
2.9
7.6
|
L
 138.1%
H
1.3
7.6
|
L
 11.7%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
164.6
|
5.8
|
L
 -4.3%
H
5.8
6.1
|
L
 -16.9%
H
5.8
6.9
|
L
 -23.1%
H
5.8
8.3
|
L
 -34.6%
H
5.8
9.6
|
L
 -57.1%
H
5.8
24.2
|
L
 -83.7%
H
5.8
45
|
L
 -81.4%
H
5.8
65
|
L
 -80.3%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,279.6
|
5.2
|
L
 -0.4%
H
5.2
5.3
|
L
 -1.9%
H
5
5.3
|
L
 -14.4%
H
4.9
6.5
|
L
 -19.7%
H
4.9
7.4
|
L
 17.5%
H
4.1
8.4
|
L
 48.9%
H
3.2
10.1
|
L
 -32.7%
H
0.5
10.1
|
L
 -46.8%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,522.3
|
28.2
|
L
 -1.2%
H
28.1
29.0
|
L
 1.5%
H
26.0
29.0
|
L
 7.4%
H
25.3
29.8
|
L
 14.8%
H
19.3
29.8
|
L
 92.0%
H
13.7
31.8
|
L
 170.8%
H
1.8
31.8
|
L
 9.4%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.0
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 5.6%
H
1.0
1.2
|
L
 -9.5%
H
1.0
1.3
|
L
 -74.3%
H
1.0
5.6
|
L
 -97.5%
H
1.0
49.3
|
L
 -96.7%
H
1.0
85.8
|
L
 -99.6%
H
1.0
356.4
|
L
H
1.0
46656
|
| Assembly Biosciences Inc |
|
522.0
|
26.3
|
L
 -1.8%
H
26.3
27
|
L
 -3.9%
H
25.4
28.2
|
L
 7.8%
H
24.0
29.9
|
L
 -9.9%
H
21.8
32.5
|
L
 41.0%
H
16.9
39.7
|
L
 97.7%
H
7.7
39.7
|
L
 -37.3%
H
7.7
47.3
|
L
 -61.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
484.7
|
3.9
|
L
 -0.8%
H
3.8
4.0
|
L
 -23.2%
H
3.6
5.0
|
L
 -46.4%
H
3.6
7.6
|
L
 -28.3%
H
3.6
8.5
|
L
 -63.3%
H
3.6
14.5
|
L
 466.2%
H
0.7
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
2,637.8
|
7.1
|
L
 -1.3%
H
7.1
7.2
|
L
 37.9%
H
4.8
7.2
|
L
 75.6%
H
4.0
7.2
|
L
 76.9%
H
3.7
7.2
|
L
 120.7%
H
3.1
7.2
|
L
 230.1%
H
1.0
7.2
|
L
 -58.1%
H
1.0
17.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
72.9
|
5.5
|
L
 -2.8%
H
5.5
5.8
|
L
 -7.4%
H
5.5
7
|
L
 9.3%
H
4.8
7.2
|
L
 28.7%
H
3.5
7.2
|
L
 -70.6%
H
1.8
174.6
|
L
 -97.3%
H
1.8
212.8
|
L
 -100.0%
H
1.8
34401.4
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
23.9
|
2.4
|
L
 -3.6%
H
2.4
2.5
|
L
 1.3%
H
2.2
2.5
|
L
 19.4%
H
1.7
2.6
|
L
 -58.8%
H
1.7
6.3
|
L
 -81%
H
1.7
19.4
|
L
 -85.0%
H
1.7
34.7
|
L
 -95.9%
H
1.7
68.6
|
L
 -99.7%
H
1.7
806.5
|
| Atara Biotherapeutics Inc |
|
75.6
|
8.4
|
L
H
8.1
8.8
|
L
 -14.0%
H
7.9
9.6
|
L
 -16.7%
H
7.9
12
|
L
 59.2%
H
4.5
12.5
|
L
 -16.1%
H
3.9
19.1
|
L
 -84.2%
H
0.4
63.4
|
L
 -97.4%
H
0.4
501
|
L
 -98.4%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
396.1
|
5.0
|
L
 1.6%
H
4.9
5.0
|
L
 -0.8%
H
4.6
5
|
L
 13.5%
H
4.3
5.0
|
L
 -13.8%
H
4.0
5.8
|
L
 47.3%
H
2.8
6.5
|
L
 34.9%
H
2.5
6.5
|
L
 -80.1%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
963.0
|
18.3
|
L
 -5.4%
H
18.3
19.8
|
L
 -4.6%
H
17.5
19.8
|
L
 24.6%
H
14.7
20.7
|
L
 27.0%
H
12.5
24.3
|
L
 193.1%
H
6.2
24.3
|
L
 5809.7%
H
0.0
34.5
|
L
 -46.4%
H
0.0
38.9
|
L
 -34.5%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
23.3
|
2.2
|
L
 0.9%
H
2.2
2.2
|
L
 -3.6%
H
2.1
2.3
|
L
 -6.1%
H
2.1
2.3
|
L
 -16.5%
H
2.0
2.6
|
L
 -8.4%
H
1.7
3.1
|
L
 19.9%
H
1.0
3.5
|
L
 -97.4%
H
1.0
88.4
|
L
 -100.0%
H
1.0
323200
|
| Adagene Inc (ADR) |
|
240.5
|
3.6
|
L
 1.4%
H
3.6
3.8
|
L
 -7.6%
H
3.3
4.1
|
L
 -7.6%
H
3.3
4.9
|
L
 -8.3%
H
3.1
4.9
|
L
 108%
H
1.3
4.9
|
L
 175.8%
H
1.1
4.9
|
L
 -80.5%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.2
|
5.7
|
L
H
5.7
6.2
|
L
 -10.1%
H
5.7
6.5
|
L
 -8.1%
H
5.6
6.8
|
L
 -15.2%
H
5.6
7.5
|
L
 -24.4%
H
5.4
12.1
|
L
 -52.1%
H
5
27.9
|
L
 -97.0%
H
5
205.6
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
286.2
|
13.7
|
L
 -2.1%
H
13.7
14.2
|
L
 -8.3%
H
13.7
15.0
|
L
 -14.9%
H
13.7
17.3
|
L
 -8.9%
H
13.0
17.3
|
L
 -13.7%
H
13.0
20.9
|
L
 1163.9%
H
0.4
20.9
|
L
 223.5%
H
0.4
20.9
|
L
 496.1%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
15,878.1
|
258.6
|
L
 -0.9%
H
258.2
263.3
|
L
 -4.4%
H
258.2
268.8
|
L
 12.0%
H
222.8
282.2
|
L
 5.8%
H
203.8
282.2
|
L
 52.2%
H
160.9
282.2
|
L
 185.7%
H
85.3
282.2
|
L
 112.8%
H
61.6
282.2
|
L
 1908.0%
H
12.8
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
87.0
|
4.8
|
L
 -3.6%
H
4.6
5
|
L
 -11.6%
H
4.6
5.5
|
L
 -1.6%
H
4.6
5.9
|
L
 7.4%
H
3.8
5.9
|
L
 -4%
H
2.7
7
|
L
 66.1%
H
1
7
|
L
 -64.4%
H
1
18.2
|
L
 -89.4%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
377.9
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -11.8%
H
1.4
1.6
|
L
 -6.0%
H
1.4
1.7
|
L
 -11.3%
H
1.4
2.0
|
L
 -41.1%
H
1.2
2.7
|
L
 -47.4%
H
1.1
7.5
|
L
 -76.6%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
518,073.7
|
167.1
|
L
 -1.1%
H
167.0
168.7
|
L
 -2.6%
H
164.5
170.5
|
L
 -4.5%
H
164.5
196.4
|
L
 -18.4%
H
164.5
203.4
|
L
 -11.3%
H
164.5
212.7
|
L
 -11.3%
H
164.5
212.7
|
L
 -11.3%
H
164.5
212.7
|
L
 -11.3%
H
164.5
212.7
|
| Biofrontera Inc |
|
13.8
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 9.1%
H
0.9
1.2
|
L
 -1.8%
H
0.7
1.2
|
L
 22.7%
H
0.6
1.2
|
L
 -88.3%
H
0.5
13.0
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
30,067.8
|
203.7
|
L
 -1.1%
H
202.1
205.7
|
L
 2.3%
H
186.0
215.8
|
L
 3.6%
H
186.0
219.7
|
L
 14.8%
H
178.7
219.7
|
L
 62.9%
H
121.1
219.7
|
L
 -26.4%
H
110.0
280.4
|
L
 -37.2%
H
110.0
351.9
|
L
 -14.9%
H
110.0
468.6
|
| Biomea Fusion Inc |
|
91.8
|
1.3
|
L
 -0.8%
H
1.3
1.3
|
L
 -3.8%
H
1.2
1.4
|
L
 7.6%
H
1.2
1.5
|
L
 -42.5%
H
1.1
2.2
|
L
 -31.4%
H
0.9
3.0
|
L
 -94.1%
H
0.9
23.1
|
L
 -90.6%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
8.5
|
4.4
|
L
H
4.1
4.4
|
L
 16.9%
H
3.8
4.4
|
L
 10.8%
H
3.8
4.4
|
L
 -6.6%
H
3.8
5.7
|
L
 -20.1%
H
3.8
7.2
|
L
 -84.5%
H
3.8
31.2
|
L
 -98.4%
H
3.8
385.7
|
L
H
3.8
861.4
|
| BeyondSpring Inc |
|
53.0
|
1.3
|
L
H
1.2
1.3
|
L
 -10.4%
H
1.2
1.6
|
L
 -19.9%
H
1.2
1.9
|
L
 -25.4%
H
1.2
1.9
|
L
 -40.8%
H
1.2
2.4
|
L
 19.4%
H
0.7
4
|
L
 -87.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
291.1
|
4.2
|
L
 -1.0%
H
4.2
4.3
|
L
 -5.4%
H
4.1
4.4
|
L
 4.3%
H
3.9
4.5
|
L
 -21.8%
H
3.9
5.3
|
L
 -51.3%
H
3.9
9.2
|
L
 -83.2%
H
3.9
28.7
|
L
 -87.9%
H
3.9
62.1
|
L
H
3.9
62.1
|
| Biodexa Pharma PLC (ADR) |
|
1.8
|
2
|
L
 -6.1%
H
2
2.2
|
L
 -19.7%
H
2
2.5
|
L
 -34.6%
H
2
3.1
|
L
 -42.5%
H
2
5.1
|
L
 -95.3%
H
2
59.4
|
L
 -100.0%
H
2
301250
|
L
 -100.0%
H
2
104500000
|
L
 -100.0%
H
2
10000000000
|
| Bioline Rx Ltd (ADR) |
|
13.3
|
3.1
|
L
 5.5%
H
2.9
3.1
|
L
 -1.0%
H
2.9
3.2
|
L
 -3.2%
H
2.8
3.5
|
L
 24.9%
H
2.2
4.0
|
L
 -31.5%
H
2.2
4.8
|
L
 -95.3%
H
0.1
101.2
|
L
 -97.6%
H
0.1
137.2
|
L
 -99.3%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,203.2
|
154.8
|
L
 3.1%
H
150.6
155.2
|
L
 3.6%
H
144.1
155.2
|
L
 5.9%
H
141.0
158.9
|
L
 -6.5%
H
130
173.3
|
L
 154.0%
H
59.1
200
|
L
 867.2%
H
15
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
18.3
|
3.4
|
L
 -0.9%
H
3.4
3.5
|
L
 -4.2%
H
3.4
3.7
|
L
 -21.4%
H
3.2
4.6
|
L
 -28.9%
H
3.2
5.5
|
L
 -54.5%
H
3.2
21.4
|
L
 28.9%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,101.5
|
19.0
|
L
 -2.2%
H
18.9
20.2
|
L
 -11.6%
H
18.6
21.5
|
L
 -33.0%
H
18.6
30.9
|
L
 -45.2%
H
18.6
36.8
|
L
 176.5%
H
4.3
40.4
|
L
 329.3%
H
2.7
40.4
|
L
 317.1%
H
2.6
40.4
|
L
 -54.5%
H
0.9
44.4
|
| Crescent Biopharma Inc |
|
-
|
14.7
|
L
 -0.4%
H
14.5
15.4
|
L
 -15.3%
H
14.5
17.4
|
L
 -17.0%
H
14.5
19.2
|
L
 -31.0%
H
14.5
27.4
|
L
 10.1%
H
8.7
27.4
|
L
 165.6%
H
4.8
27.4
|
L
 39.6%
H
0.9
27.4
|
L
 -70.5%
H
0.9
90.3
|
| Cullinan Oncology Inc |
|
1,084.1
|
17.6
|
L
 -0.3%
H
17.6
18.4
|
L
 -2.7%
H
16
18.4
|
L
 17.4%
H
15.3
19.4
|
L
 17.1%
H
11.7
19.4
|
L
 134.3%
H
5.7
19.4
|
L
 58.2%
H
5.7
30.2
|
L
 -33.5%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
215.9
|
1.4
|
L
H
1.4
1.4
|
L
 -9.1%
H
1.4
1.5
|
L
 -5.4%
H
1.4
1.7
|
L
 -29.3%
H
1.3
2.1
|
L
 59.1%
H
0.8
2.6
|
L
 -68.0%
H
0.7
5.5
|
L
 -89.2%
H
0.7
19.3
|
L
 -94.1%
H
0.7
32.0
|
| Cingulate Inc |
|
59.9
|
4.5
|
L
 -2.0%
H
4.4
4.6
|
L
 -9.4%
H
4.2
4.9
|
L
 -10.8%
H
4.2
6.0
|
L
 -18.4%
H
3.2
6.6
|
L
 -13.9%
H
3.2
11.9
|
L
 477.9%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
75.1
|
5.9
|
L
 -0.7%
H
5.8
6.0
|
L
 -6.2%
H
5.6
6.6
|
L
 -2.2%
H
5.6
6.6
|
L
 -6.8%
H
5.2
8.7
|
L
 53.9%
H
3.3
13.5
|
L
 -64.1%
H
2.3
16.4
|
L
 -96.6%
H
2.3
196.8
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
19.9
|
2.5
|
L
 -0.8%
H
2.5
2.5
|
L
 -11.7%
H
2.5
2.8
|
L
 -10.8%
H
2.5
3.1
|
L
 -14.7%
H
2.2
4.7
|
L
 -50.1%
H
2.2
6.5
|
L
 -95.7%
H
2.2
133.5
|
L
 -99.2%
H
2.2
345
|
L
 -100.0%
H
2.2
10410
|
| Compass Therapeutics Inc |
|
365.6
|
2.0
|
L
 -1.0%
H
2.0
2.1
|
L
 -12.9%
H
2.0
2.3
|
L
 0.5%
H
2.0
2.4
|
L
 -66.2%
H
1.6
6.2
|
L
 -32.3%
H
1.6
6.9
|
L
 -24.3%
H
0.8
6.9
|
L
 -59.4%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
7.4
|
5.1
|
L
 0.6%
H
5.0
5.1
|
L
 -1.7%
H
4.6
5.3
|
L
 7.9%
H
3.9
5.5
|
L
 99.6%
H
1.9
10.5
|
L
 -47.2%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
83250000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
56.0
|
0.6
|
L
 1.7%
H
0.6
0.6
|
L
 -6.2%
H
0.6
0.7
|
L
 -3.2%
H
0.5
0.7
|
L
 -74.9%
H
0.5
3.1
|
L
 -31.5%
H
0.5
3.6
|
L
 -45.0%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
13.2
|
1.0
|
L
 1.1%
H
1.0
1.0
|
L
 -5.0%
H
0.9
1.0
|
L
 -4%
H
0.9
1.1
|
L
 -36.4%
H
0.9
1.5
|
L
 -41.5%
H
0.9
2.7
|
L
 -65.0%
H
0.9
3.3
|
L
 -93.0%
H
0.9
17.9
|
L
 -99.5%
H
0.9
205.2
|
| Collegium pharma Inc |
|
1,158.5
|
35.7
|
L
 -1%
H
35.5
36.9
|
L
 1.4%
H
34.3
37.7
|
L
 6.5%
H
32.9
38.5
|
L
 3.8%
H
30.1
40.5
|
L
 14.5%
H
29.2
50.8
|
L
 64.4%
H
21.0
50.8
|
L
 47.7%
H
14.0
50.8
|
L
 194.7%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
9,810.9
|
91.4
|
L
 1.0%
H
90.1
92.2
|
L
 -0.5%
H
84.9
92.6
|
L
 14.4%
H
77.4
95.1
|
L
 98.0%
H
44.2
95.1
|
L
 29.0%
H
28.7
95.1
|
L
 296.1%
H
20.8
117.3
|
L
 344.7%
H
15.8
117.3
|
L
 1509.0%
H
5.2
117.3
|
| Cosmos Health Inc |
|
14.3
|
0.2
|
L
 -4.2%
H
0.2
0.2
|
L
 -20.7%
H
0.2
0.4
|
L
 9.5%
H
0.2
0.4
|
L
 -43.9%
H
0.2
0.4
|
L
 -47.7%
H
0.2
1.3
|
L
 -90.7%
H
0.2
2.1
|
L
 -99.8%
H
0.2
150
|
L
 -99.8%
H
0.2
312.5
|
| Cumberland Pharma Inc |
|
111.5
|
7.4
|
L
 8.8%
H
7.1
7.8
|
L
 25.5%
H
5.8
8.1
|
L
 30.1%
H
5.5
8.1
|
L
 130.3%
H
3.0
8.1
|
L
 131.1%
H
1.9
8.1
|
L
 389.5%
H
1.0
8.1
|
L
 138.5%
H
1.0
8.1
|
L
 60%
H
1.0
8.1
|
| Corbus Pharma Holdings Inc |
|
164.5
|
8.9
|
L
 -1.4%
H
8.9
9.2
|
L
 -8.3%
H
8.5
9.6
|
L
 7.5%
H
8.1
9.9
|
L
 -16.2%
H
7.1
12.9
|
L
 4.5%
H
7.1
20.6
|
L
 19.8%
H
3.0
61.9
|
L
 -79.2%
H
2.1
61.9
|
L
 -89.1%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
8,875.8
|
83.9
|
L
H
83.8
83.9
|
L
 0.3%
H
83.6
84
|
L
 133.8%
H
34.7
84
|
L
 104.5%
H
32.3
84
|
L
 169.6%
H
25.8
84
|
L
 327.6%
H
15.8
84
|
L
 330.9%
H
15.2
84
|
L
H
10.6
84
|
| Corvus Pharma Inc |
|
1,204.2
|
14.3
|
L
 -3.9%
H
14.3
15.2
|
L
 -8.6%
H
13.9
15.6
|
L
 20.2%
H
12.1
16.5
|
L
 -14.5%
H
10.8
19.7
|
L
 236.2%
H
4.0
27.0
|
L
 430.4%
H
1.1
27.0
|
L
 556.9%
H
0.6
27.0
|
L
 0.8%
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
788.1
|
3.6
|
L
H
3.6
3.7
|
L
 -3.7%
H
3.5
3.8
|
L
 22.7%
H
3.0
4.0
|
L
 -24.9%
H
2.8
5.1
|
L
 52.1%
H
1.7
8.2
|
L
 98.9%
H
0.4
8.2
|
L
 -36.6%
H
0.4
8.2
|
L
 -65.0%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
5.0
|
0.9
|
L
 -4.2%
H
0.9
0.9
|
L
 1.1%
H
0.8
1.0
|
L
 19.7%
H
0.6
1.2
|
L
 -13.3%
H
0.6
2.8
|
L
 -93.0%
H
0.6
19.9
|
L
 -100.0%
H
0.6
2826
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
15.6
|
3.6
|
L
 -0.8%
H
3.6
3.6
|
L
 -6.0%
H
3.6
3.9
|
L
 12.8%
H
3.0
4.0
|
L
 19.5%
H
2.8
4.0
|
L
 2.0%
H
1.0
8.5
|
L
 0.3%
H
1.0
8.5
|
L
 -94.6%
H
1.0
84.6
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,898.3
|
80.3
|
L
 0.1%
H
79.7
81.3
|
L
 -5.4%
H
78.3
84.6
|
L
 1.9%
H
78.3
88.3
|
L
 20.3%
H
58.6
88.3
|
L
 115.6%
H
32.9
88.3
|
L
 138.8%
H
26.0
110
|
L
 197.3%
H
26.0
110
|
L
 740.5%
H
5.8
110
|
| Cellectis (ADR) |
|
260.8
|
2.6
|
L
 -1.5%
H
2.6
2.7
|
L
 -13.4%
H
2.6
3.0
|
L
 -13.1%
H
2.6
3.4
|
L
 -41.4%
H
2.6
4.2
|
L
 42.3%
H
1.8
5.5
|
L
 14.1%
H
1.0
5.5
|
L
 -81.1%
H
1.0
15.5
|
L
 -89.7%
H
1.0
38.9
|
| Connect Biopharma Holdings Ltd (ADR) |
|
127.6
|
2.3
|
L
 -3.8%
H
2.3
2.4
|
L
 -8.8%
H
2.2
2.6
|
L
 14.5%
H
1.9
2.8
|
L
 -18.5%
H
1.9
3.0
|
L
 33.1%
H
1.2
3.8
|
L
 102.7%
H
0.5
3.8
|
L
 -90.8%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
22.5
|
1.5
|
L
 -23.5%
H
1.5
1.9
|
L
 -25.7%
H
1.5
2.1
|
L
 -30.9%
H
1.5
2.2
|
L
 -49.2%
H
1.5
3.8
|
L
 -40.5%
H
1.3
3.8
|
L
 -84.4%
H
0.3
9.7
|
L
 -91.8%
H
0.3
30.1
|
L
 -99.6%
H
0.3
429.6
|
| Journey Medical Corp |
|
197.1
|
7.2
|
L
H
7.1
7.3
|
L
 3.6%
H
6.7
7.5
|
L
 15.1%
H
6.2
7.5
|
L
 32.8%
H
4.8
7.5
|
L
 -0.4%
H
4.3
9.6
|
L
 293.4%
H
1.6
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Dermata Therapeutics Inc |
|
5.3
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 12.0%
H
1.2
1.5
|
L
 -3.7%
H
1.2
1.5
|
L
 101.5%
H
0.6
7.1
|
L
 -16.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
834.5
|
14.1
|
L
 -4.1%
H
14.1
14.4
|
L
 -14.5%
H
14.1
16.7
|
L
 -9.2%
H
14.1
17.4
|
L
 -33.9%
H
14.1
21.4
|
L
 41%
H
8.5
26.2
|
L
 -17.1%
H
0.5
26.2
|
L
 -71.6%
H
0.5
59.9
|
L
 -95.9%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
59.5
|
6.2
|
L
 -6.4%
H
6.0
6.5
|
L
 -11.8%
H
6.0
7.2
|
L
 -15.9%
H
6.0
8.9
|
L
 4.2%
H
4.6
20.3
|
L
 157.5%
H
0.7
20.3
|
L
 5.1%
H
0.7
20.3
|
L
 -83.1%
H
0.7
84
|
L
 -99.3%
H
0.7
982.0
|
| Eledon Pharma Inc |
|
308.8
|
4
|
L
 -1.7%
H
4
4.2
|
L
 3.9%
H
3.8
4.2
|
L
 2.0%
H
3.6
4.5
|
L
 0.5%
H
3.3
4.5
|
L
 8.1%
H
1.4
4.6
|
L
 192.0%
H
1.1
5.4
|
L
 -43.7%
H
1.1
8.5
|
L
 -99.5%
H
1.1
900.7
|
| Enanta Pharma Inc |
|
381.2
|
13.1
|
L
 -4.6%
H
13.1
14.0
|
L
 -4.3%
H
12.8
14.0
|
L
 3.6%
H
12.7
15.5
|
L
 -6.4%
H
10.9
15.9
|
L
 73.9%
H
6.5
17.2
|
L
 -30.9%
H
4.1
20.0
|
L
 -68.9%
H
4.1
102
|
L
 -38.5%
H
4.1
127.8
|
| Entera Bio Ltd |
|
94.6
|
1.9
|
L
 -3.0%
H
1.9
2.0
|
L
 15.7%
H
1.6
2.1
|
L
 58.7%
H
1.2
2.8
|
L
 50%
H
1.1
2.8
|
L
 -6.3%
H
0.9
3.2
|
L
 134.1%
H
0.5
3.4
|
L
 -62.9%
H
0.5
5.8
|
L
H
0.5
10.2
|
| Evolus Inc |
|
366.8
|
5.6
|
L
 -2.8%
H
5.5
5.8
|
L
 -15.7%
H
5.5
6.6
|
L
 -16.0%
H
5.5
7.3
|
L
 18.8%
H
4.6
7.3
|
L
 -39.5%
H
3.9
10.2
|
L
 -26.6%
H
3.9
17.8
|
L
 -47.4%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
6,647.5
|
19.2
|
L
 -0.1%
H
19.1
19.8
|
L
 3.4%
H
17.6
21.6
|
L
 40.1%
H
14.0
21.6
|
L
 0.7%
H
8.7
24.3
|
L
 1176.7%
H
1.3
24.3
|
L
 606.6%
H
1.0
24.3
|
L
 6.8%
H
1.0
24.5
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
6.8
|
5.8
|
L
 -9.0%
H
5.3
6.4
|
L
 -3.6%
H
5.3
9.9
|
L
 -5.8%
H
5.2
9.9
|
L
 12.3%
H
3.2
15.9
|
L
 -88.2%
H
3.2
71.5
|
L
 -99.5%
H
3.2
1110
|
L
 -100.0%
H
3.2
102225
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,124.7
|
41.1
|
L
 -3.0%
H
41.1
42.5
|
L
 12.2%
H
35
42.7
|
L
 26.4%
H
31.9
42.7
|
L
 64.0%
H
22.5
42.7
|
L
 173.4%
H
13.8
42.7
|
L
 1264.1%
H
2.4
42.7
|
L
 653.4%
H
2.0
42.7
|
L
H
2.0
42.7
|
| Exelixis Inc |
|
14,221.7
|
56.6
|
L
 1.2%
H
55.8
56.7
|
L
 0.1%
H
54.4
56.8
|
L
 9%
H
50.8
57.6
|
L
 26.0%
H
43.5
57.6
|
L
 27.2%
H
33.8
57.6
|
L
 189.6%
H
18.6
57.6
|
L
 247.1%
H
14.9
57.6
|
L
 576.0%
H
8.3
57.6
|
| Hyperion DeFi Inc |
|
41.2
|
2.7
|
L
 -0.7%
H
2.7
2.8
|
L
 -12.0%
H
2.6
3.1
|
L
 -21.2%
H
2.6
3.9
|
L
 -39.0%
H
2.5
5.0
|
L
 -78.9%
H
2.5
15
|
L
 -98.5%
H
0.0
205.6
|
L
 -99.3%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,087.4
|
13.0
|
L
 -2.5%
H
13.0
13.8
|
L
 -11.9%
H
12.6
14.7
|
L
 -4.5%
H
12.6
15.9
|
L
 -13.1%
H
11.3
15.9
|
L
 24.5%
H
9.4
19.1
|
L
 8.4%
H
3.9
31.0
|
L
 65.2%
H
2.2
31.0
|
L
 -61.1%
H
2.2
42.5
|
| Fortress Biotech Inc |
|
112.9
|
3.4
|
L
 1.2%
H
3.4
3.5
|
L
 3.0%
H
3.3
3.8
|
L
 13.7%
H
2.7
3.8
|
L
 44.1%
H
2.2
3.8
|
L
 74.4%
H
1.8
4.5
|
L
 -56.4%
H
1.2
10.4
|
L
 -92.8%
H
1.2
57.2
|
L
 -92.0%
H
1.2
91.5
|
| Kyntra Bio Inc |
|
29.3
|
7.2
|
L
 0.1%
H
7.2
7.2
|
L
 -4.7%
H
7.2
7.7
|
L
 8.1%
H
6.7
7.8
|
L
 -1.1%
H
6.6
8.0
|
L
 -5.4%
H
6.3
12.6
|
L
 -87.8%
H
4.5
73.3
|
L
 -97.9%
H
4.5
642.3
|
L
 -98.3%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
340.2
|
14.8
|
L
 -1.7%
H
14.5
16
|
L
 32.0%
H
14.5
23.6
|
L
 24.4%
H
10.6
23.6
|
L
 153.0%
H
4.8
23.6
|
L
 572.7%
H
1.6
23.6
|
L
 -17.8%
H
1.3
53.8
|
L
 -87.0%
H
1.3
160.2
|
L
H
1.3
572.4
|
| Fulcrum Therapeutics Inc |
|
239.2
|
3.6
|
L
 -1.6%
H
3.6
3.8
|
L
 2.6%
H
3.4
3.8
|
L
 -3.0%
H
3.4
4.0
|
L
 -56.7%
H
2.8
8.4
|
L
 -53.1%
H
2.8
15.7
|
L
 -18.4%
H
2.3
15.7
|
L
 -63.5%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
1,943.7
|
28.3
|
L
 -1.3%
H
27.9
29.2
|
L
 6.9%
H
25
31
|
L
 27.4%
H
21.3
31
|
L
 54.5%
H
18.4
31
|
L
 61.2%
H
11.3
31
|
L
 127.6%
H
5.1
31
|
L
 64.2%
H
5.1
31
|
L
H
5.1
31
|
| Galmed Pharma Ltd |
|
4.0
|
0.5
|
L
 -5.5%
H
0.5
0.5
|
L
 -7.1%
H
0.5
0.6
|
L
 -10.3%
H
0.5
0.7
|
L
 -31.6%
H
0.4
0.8
|
L
 -71.6%
H
0.4
2.1
|
L
 -96.6%
H
0.2
15.6
|
L
 -99.9%
H
0.2
615.6
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,975.2
|
32.1
|
L
 1.9%
H
31.5
32.5
|
L
 12.5%
H
26.3
32.5
|
L
 51.2%
H
21.5
32.5
|
L
 20.6%
H
18.6
32.5
|
L
 793.9%
H
2.5
38.3
|
L
 1231.5%
H
0.5
38.3
|
L
 642.8%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Genelux Corp |
|
125.1
|
2.8
|
L
 -2.8%
H
2.8
2.9
|
L
 -7.9%
H
2.8
3.0
|
L
 -5.7%
H
2.8
3.2
|
L
H
2.5
3.3
|
L
 -16.2%
H
2.3
8.5
|
L
 -89.7%
H
1.6
30.4
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
3.5
|
6.9
|
L
 -10.0%
H
6.7
7.5
|
L
 1132.1%
H
0.5
10.0
|
L
 1069.5%
H
0.5
10.0
|
L
 430.8%
H
0.4
10.0
|
L
 2364.3%
H
0.1
13.0
|
L
 702.3%
H
0.1
13.0
|
L
 132.3%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
78.2
|
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -5.9%
H
0.1
0.2
|
L
 -5.9%
H
0.1
0.2
|
L
 -64.4%
H
0.1
0.5
|
L
 -90.6%
H
0.1
3.9
|
L
 -91.2%
H
0.1
3.9
|
L
 -97.8%
H
0.1
15.2
|
L
H
0.1
27.2
|
| GT Biopharma Inc |
|
12.6
|
0.4
|
L
 -2.8%
H
0.4
0.4
|
L
 -16.7%
H
0.3
0.4
|
L
 -31.4%
H
0.3
0.6
|
L
 -7.9%
H
0.3
0.6
|
L
 -83.0%
H
0.3
2.3
|
L
 6.1%
H
0.2
10.7
|
L
 -96.8%
H
0.2
13
|
L
 -100.0%
H
0.2
1887
|
| Genenta Science SpA (ADR) |
|
74.3
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 2.7%
H
1.2
1.6
|
L
 -8.3%
H
1.2
2.0
|
L
 111.0%
H
0.6
2.6
|
L
 -59.2%
H
0.6
10
|
L
 -73.9%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
3,327.0
|
46.8
|
L
 -3.4%
H
46.8
49.5
|
L
 -12.3%
H
44.8
53
|
L
 5.2%
H
44.0
57.1
|
L
 -7.8%
H
35.8
57.1
|
L
 143.2%
H
15.8
94.9
|
L
 40.9%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,104.3
|
7.5
|
L
 3.2%
H
7.5
7.5
|
L
 3.2%
H
7
7.5
|
L
 1.4%
H
7.0
7.5
|
L
 -14.3%
H
7.0
8.7
|
L
 -24.6%
H
7.0
11.1
|
L
 -28.4%
H
5.3
12.2
|
L
 -50.9%
H
5.3
16.4
|
L
 -55.3%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
18.1
|
0.8
|
L
H
0.8
0.8
|
L
 -10%
H
0.8
0.9
|
L
 -25%
H
0.8
1.2
|
L
 11.0%
H
0.5
2.5
|
L
 -35.2%
H
0.5
2.5
|
L
 -68.7%
H
0.5
3.8
|
L
 -97.6%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
18.0
|
0.4
|
L
H
0.4
0.4
|
L
 -7.5%
H
0.3
0.4
|
L
 5.7%
H
0.3
0.4
|
L
 -61.1%
H
0.3
1.0
|
L
 -73.8%
H
0.3
2.4
|
L
 -89.0%
H
0.3
8.2
|
L
 -97.8%
H
0.3
21.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,966.6
|
34.0
|
L
 0.6%
H
33.8
34.3
|
L
 -7.8%
H
32.3
37.0
|
L
 2.1%
H
32.3
38.9
|
L
 13.3%
H
28.7
38.9
|
L
 -3.5%
H
25.5
40.9
|
L
 -4.5%
H
18.6
41.6
|
L
 22.7%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,676.6
|
45.0
|
L
 -3.6%
H
44.9
47.1
|
L
 5.9%
H
40.9
47.5
|
L
 4.9%
H
40.5
47.5
|
L
 8.4%
H
28.5
47.5
|
L
 25.3%
H
28.5
54.9
|
L
 108.9%
H
7.6
59.2
|
L
 529.1%
H
5.4
59.2
|
L
 1077.5%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
1,917.2
|
11.2
|
L
 2.9%
H
11.1
11.3
|
L
 0.7%
H
10.8
11.8
|
L
 8.5%
H
9.8
11.8
|
L
 -29.2%
H
9.8
15.7
|
L
 -36.6%
H
9.8
19.5
|
L
 -8.6%
H
9.8
21.9
|
L
 -72.0%
H
7.4
43.9
|
L
 -14.2%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,823.7
|
7.5
|
L
 -2.7%
H
7.5
7.8
|
L
 -9.1%
H
7.3
8.2
|
L
 1.5%
H
7
9.6
|
L
 -3.0%
H
6.7
9.6
|
L
 171.6%
H
2.0
12.4
|
L
 141.0%
H
1.3
12.4
|
L
 -32.2%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
3,460.1
|
35.9
|
L
 -0.2%
H
35.9
36.6
|
L
 -2.8%
H
35.1
37.0
|
L
 15.1%
H
31.8
40.6
|
L
 6.0%
H
26.8
40.6
|
L
 66.5%
H
21.3
40.6
|
L
 65.9%
H
13.5
47.7
|
L
 87.3%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
337.6
|
2.2
|
L
 1.9%
H
2.1
2.2
|
L
 5.4%
H
1.9
2.4
|
L
 17.5%
H
1.8
2.4
|
L
 17.5%
H
1.5
2.4
|
L
 16.9%
H
1.3
2.4
|
L
 -19.8%
H
0.8
4.2
|
L
 -84.1%
H
0.8
16.4
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
627.9
|
8.8
|
L
 -14.0%
H
8.7
10.1
|
L
 -20.6%
H
8.7
11.2
|
L
 1.2%
H
8.7
12.1
|
L
 -14.8%
H
7.7
12.1
|
L
 197.0%
H
1.9
12.1
|
L
 324.0%
H
1.3
12.1
|
L
H
0.7
12.1
|
L
H
0.7
12.1
|
| Immuneering Corp (Class A) |
|
287.3
|
4.4
|
L
 -4.3%
H
4.4
4.9
|
L
 -13.1%
H
4.4
5.2
|
L
 0.7%
H
4.4
5.7
|
L
 -20.1%
H
3.9
6.9
|
L
 7.5%
H
2.9
10.1
|
L
 -53.9%
H
1
11.1
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,262.9
|
9.2
|
L
 -3.7%
H
9.2
9.6
|
L
 -4.6%
H
9.1
9.8
|
L
 -5.5%
H
9.1
10.9
|
L
 -17.3%
H
8.8
11.9
|
L
 54%
H
5.1
12.4
|
L
 -24.0%
H
3.3
13.8
|
L
 -22.9%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
207.0
|
15.2
|
L
 0.3%
H
14.9
15.5
|
L
 2.9%
H
14.2
15.8
|
L
 7.0%
H
14.1
15.8
|
L
 52%
H
8.5
15.8
|
L
 57.7%
H
5.1
15.8
|
L
 -42.6%
H
5.1
26.9
|
L
 -83.8%
H
5.1
145
|
L
 -99.4%
H
5.1
3900
|
| Incyte |
|
23,196.7
|
116.1
|
L
 -1.0%
H
115.8
118.7
|
L
 -0.5%
H
110.6
119.6
|
L
 18.2%
H
99.8
119.6
|
L
 18.7%
H
92.2
119.6
|
L
 71.1%
H
67.2
119.6
|
L
 84.6%
H
50.3
119.6
|
L
 49.7%
H
50.3
119.6
|
L
 40.2%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
329.1
|
2.5
|
L
 -2.4%
H
2.4
2.5
|
L
 -6.1%
H
2.4
3
|
L
 -36.7%
H
2.4
4.1
|
L
 -28.4%
H
0.9
6.0
|
L
 -78.7%
H
0.9
12.0
|
L
 30.7%
H
0.3
13.4
|
L
 -80.9%
H
0.3
28.8
|
L
 -100.0%
H
0.3
8800
|
| Indivior PLC |
|
4,787.3
|
40.5
|
L
 -0.1%
H
40.3
41
|
L
H
39.3
41.8
|
L
 5.7%
H
37.6
42.8
|
L
 23.9%
H
32.0
42.8
|
L
 153.0%
H
15.6
42.8
|
L
 68.2%
H
7.3
42.8
|
L
 1810.4%
H
2.0
42.8
|
L
 1073.9%
H
0.4
42.8
|
| InMed Pharma Inc |
|
8.3
|
1.6
|
L
 2.6%
H
1.6
1.6
|
L
 -4.9%
H
1.5
1.6
|
L
 4.7%
H
1.5
1.7
|
L
 119.7%
H
0.6
2.0
|
L
 -41.6%
H
0.6
2.8
|
L
 -91.7%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1475
|
L
 -99.8%
H
0.6
32175
|
| Inovio Pharma Inc |
|
88.9
|
1.1
|
L
 -3.6%
H
1.1
1.1
|
L
 -8.5%
H
1.1
1.2
|
L
 -3.6%
H
1.1
1.3
|
L
 -9.2%
H
1.1
1.8
|
L
 -22.3%
H
1.0
3.0
|
L
 86.2%
H
0.3
14.8
|
L
 -87.9%
H
0.3
14.8
|
L
 -87.7%
H
0.3
33.8
|
| Insmed Inc |
|
23,517.6
|
108.5
|
L
 0.2%
H
107.3
109.8
|
L
 -6.2%
H
105.1
115.6
|
L
 13.3%
H
95.3
119.5
|
L
 -24.9%
H
90.4
145.4
|
L
 5.8%
H
90.4
212.8
|
L
 414.0%
H
20.2
212.8
|
L
 322.2%
H
16.0
212.8
|
L
 901.8%
H
10.2
212.8
|
| Innoviva Inc |
|
1,594.3
|
21.6
|
L
 -0.5%
H
21.5
21.8
|
L
 -2.9%
H
21.5
22.7
|
L
 -4.0%
H
21.5
24.2
|
L
 -10.9%
H
21.2
24.5
|
L
 10.4%
H
16.5
25.1
|
L
 69.1%
H
12.2
25.1
|
L
 62.4%
H
10.6
25.1
|
L
 89.1%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
8,983.7
|
54.4
|
L
 -0.1%
H
53.6
54.8
|
L
 -6.7%
H
53.4
57.9
|
L
 -26.7%
H
53.4
86.7
|
L
 -28.2%
H
53.4
86.7
|
L
 30.2%
H
40.0
86.7
|
L
 29.3%
H
24.0
86.7
|
L
 52.9%
H
24.0
86.7
|
L
 103.9%
H
24.0
86.7
|
| Ironwood Pharma Inc (Class A) |
|
645.3
|
3.9
|
L
 1.6%
H
3.9
4.0
|
L
 -12.3%
H
3.8
4.4
|
L
 10.7%
H
3.6
4.9
|
L
 -11.5%
H
3.1
4.9
|
L
 409.1%
H
0.7
5.8
|
L
 -62.6%
H
0.5
15.7
|
L
 -68.9%
H
0.5
15.7
|
L
 -65.4%
H
0.5
17.7
|
| Immuron Ltd (ADR) |
|
9.4
|
1.2
|
L
 -4.1%
H
1.2
1.2
|
L
 -5.7%
H
1.1
1.3
|
L
 9.4%
H
1.0
1.4
|
L
 20.8%
H
0.8
1.6
|
L
 -32.2%
H
0.7
2.4
|
L
 -42%
H
0.7
6.0
|
L
 -76.1%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
164.3
|
1.8
|
L
H
1.7
1.8
|
L
 -2.2%
H
1.7
1.9
|
L
 -3.3%
H
1.7
2.0
|
L
 5.4%
H
1.3
2.6
|
L
 -8.9%
H
1.2
2.6
|
L
 -45.5%
H
1.2
3.5
|
L
 -42.4%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
5.8
|
1.2
|
L
 -9.2%
H
1.2
1.3
|
L
 -48.9%
H
1.0
2.3
|
L
 -47.6%
H
1.0
3.1
|
L
 -91.5%
H
1.0
15.2
|
L
 -98.6%
H
1.0
92.8
|
L
 -100.0%
H
1.0
36540
|
L
 -100.0%
H
1.0
19254375
|
L
 -100.0%
H
1.0
880621875
|
| Jazz Pharma PLC |
|
15,482.0
|
246.5
|
L
 -0.4%
H
245.8
249.9
|
L
 1.1%
H
233.5
249.9
|
L
 9.7%
H
222.9
250.5
|
L
 21.2%
H
194.8
250.5
|
L
 118.4%
H
105
250.5
|
L
 87.9%
H
95.5
250.5
|
L
 43.7%
H
95.5
250.5
|
L
 75.0%
H
86.9
250.5
|
| Kala Pharma Inc |
|
14.1
|
0.8
|
L
 -2.6%
H
0.8
0.8
|
L
 -35.6%
H
0.8
1.2
|
L
 -79.0%
H
0.8
3.7
|
L
 -92.4%
H
0.8
10.4
|
L
 -99.7%
H
0.8
1030
|
L
 -99.9%
H
0.8
1030
|
L
 -100.0%
H
0.8
10035.3
|
L
H
0.8
66943.3
|
| Kiniksa Pharma Ltd (Class A) |
|
4,876.3
|
63.4
|
L
 -0.9%
H
63.4
65
|
L
 -0.1%
H
60.1
65
|
L
 15.0%
H
55.7
67.5
|
L
 41.2%
H
41.5
67.5
|
L
 118.4%
H
26.3
67.5
|
L
 304.7%
H
14.1
67.5
|
L
 367.1%
H
7.4
67.5
|
L
H
5.0
67.5
|
| Kiora Pharma Inc |
|
11.3
|
2.6
|
L
 -3.0%
H
2.5
2.6
|
L
 1.6%
H
2.4
2.6
|
L
 0.8%
H
2.4
2.7
|
L
 1.2%
H
2.3
2.9
|
L
 -19.8%
H
1.8
3.2
|
L
 298.4%
H
0.4
5.6
|
L
 -98.1%
H
0.4
257.2
|
L
 -99.8%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
178.8
|
7.9
|
L
 -17.0%
H
7.8
9.5
|
L
 -23.7%
H
7.8
10.3
|
L
 -12.5%
H
7.8
10.9
|
L
 -8.4%
H
6.9
10.9
|
L
 104.9%
H
3.7
11.0
|
L
 -67.1%
H
0.6
29.3
|
L
 -94.2%
H
0.6
221.0
|
L
 -92.6%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
210.4
|
10.6
|
L
 -0.1%
H
10.6
11.0
|
L
 -9.9%
H
10.4
11.8
|
L
 -0.2%
H
10.3
12.2
|
L
 -8.9%
H
9.7
12.2
|
L
 -22.7%
H
9.7
22.6
|
L
 -75.3%
H
9.1
73
|
L
 -73.1%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
16.4
|
0.5
|
L
 8.9%
H
0.5
0.5
|
L
H
0.4
0.5
|
L
 -2%
H
0.4
0.6
|
L
 -33.8%
H
0.4
1.0
|
L
 -31.9%
H
0.3
2.1
|
L
 4.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Lexaria Bioscience Corp |
|
14.6
|
0.6
|
L
 -7.8%
H
0.6
0.6
|
L
 -9.2%
H
0.5
0.7
|
L
 9.3%
H
0.5
0.7
|
L
 -42.7%
H
0.5
1.1
|
L
 -37.9%
H
0.5
1.6
|
L
 -24.4%
H
0.5
6.9
|
L
 -90.7%
H
0.5
12.5
|
L
 -85.3%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
173.3
|
4.6
|
L
 -1.3%
H
4.6
5.0
|
L
 -2.7%
H
4.5
5.3
|
L
 -16.6%
H
4.5
6.0
|
L
 -14.1%
H
4.2
6.0
|
L
 -38.3%
H
3.6
9.0
|
L
 -53.9%
H
3.6
11.5
|
L
 -61.4%
H
1.5
12.6
|
L
 -58.2%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
6,022.1
|
300.5
|
L
 -1.0%
H
300.5
308.6
|
L
 -5.0%
H
290.2
316.4
|
L
 9.3%
H
245
326.6
|
L
 29.6%
H
200.0
326.6
|
L
 116.0%
H
129.6
326.6
|
L
 344.4%
H
49.3
326.6
|
L
 283.7%
H
46.8
326.6
|
L
 263.7%
H
36.9
326.6
|
| Atyr Pharma Inc |
|
49.0
|
0.5
|
L
 -2.0%
H
0.5
0.5
|
L
 -7.4%
H
0.5
0.6
|
L
 11.1%
H
0.5
0.7
|
L
 -41.2%
H
0.4
1.1
|
L
 -91.7%
H
0.4
7.3
|
L
 -74.4%
H
0.4
7.3
|
L
 -88.2%
H
0.4
13.1
|
L
 -98.6%
H
0.4
90.9
|
| Lipocine Inc |
|
18.2
|
2.2
|
L
 -0.9%
H
2.2
2.2
|
L
 -8.3%
H
2.2
2.5
|
L
 -5.2%
H
2.2
2.7
|
L
 -9.1%
H
1.9
2.7
|
L
 -29.2%
H
1.8
12.4
|
L
 -49.2%
H
1.8
12.4
|
L
 -89.8%
H
1.8
32.1
|
L
 -96.0%
H
1.8
100.3
|
| Liquidia Corp |
|
7,054.7
|
79.3
|
L
 -0.8%
H
79.0
81.5
|
L
 1.8%
H
69.7
81.5
|
L
 11.6%
H
69.7
83.0
|
L
 101.0%
H
35.8
83.0
|
L
 445.6%
H
14.4
83.0
|
L
 901.6%
H
5.7
83.0
|
L
 3111.7%
H
2.3
83.0
|
L
H
2.3
83.0
|
| Lisata Therapeutics Inc |
|
31.8
|
3.5
|
L
 -3.1%
H
3.5
3.5
|
L
 6.7%
H
3.3
3.9
|
L
 -0.9%
H
3.2
3.9
|
L
 8.1%
H
2.8
4.0
|
L
 37.9%
H
1.8
5.1
|
L
 -5.2%
H
1.8
5.1
|
L
 -83.1%
H
1.8
21.6
|
L
 -95.8%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
37.3
|
2.9
|
L
 1.7%
H
2.9
3.1
|
L
 -18.9%
H
2.8
3.8
|
L
 -23.0%
H
2.8
4.3
|
L
 17.3%
H
2.0
4.3
|
L
 -26.8%
H
1.1
5.7
|
L
 -36.8%
H
1.1
12.0
|
L
 -77.1%
H
1.1
15
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
1,017.2
|
2.3
|
L
 -4.2%
H
2.3
2.4
|
L
 3.2%
H
2.0
2.4
|
L
 13.9%
H
2.0
2.7
|
L
 22.5%
H
1.5
2.7
|
L
 86.2%
H
1
2.7
|
L
 5.0%
H
0.3
3.7
|
L
 -37.9%
H
0.3
6.3
|
L
 -84.4%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
4,435.6
|
22.9
|
L
 3.0%
H
22.1
23.2
|
L
 -15.3%
H
22.1
26.8
|
L
 -17.9%
H
22.1
30.3
|
L
 8.3%
H
21.7
37.5
|
L
 -44.9%
H
16.2
45.3
|
L
 -67.4%
H
16.2
77.3
|
L
 -47.7%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.8
|
0.6
|
L
H
0.6
0.6
|
L
 -10%
H
0.6
0.7
|
L
 -3.1%
H
0.6
0.8
|
L
 -18.2%
H
0.6
0.9
|
L
 -71.1%
H
0.5
2.2
|
L
 -99.7%
H
0.1
273.8
|
L
 -100.0%
H
0.1
2317.5
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
14.6
|
2.1
|
L
 -1.9%
H
2.1
2.1
|
L
 -9.7%
H
2.1
2.3
|
L
 -28.5%
H
2.1
3.7
|
L
 -14.9%
H
2
3.7
|
L
 -89.7%
H
1.8
21.5
|
L
 -99.2%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
 -100.0%
H
1.8
16560
|
| Madrigal Pharma Inc |
|
12,429.3
|
539.1
|
L
 -2.6%
H
538.9
555.1
|
L
 0.5%
H
522.7
560.1
|
L
 6.6%
H
500.8
569.4
|
L
 1.3%
H
445.2
569.4
|
L
 61.3%
H
286.4
615
|
L
 148.7%
H
119.8
615
|
L
 486.7%
H
52.3
615
|
L
 5824.2%
H
6.6
615
|
| MediWound Ltd |
|
187.8
|
14.6
|
L
H
14.5
14.7
|
L
 2.2%
H
14
14.8
|
L
 2.6%
H
13.9
15.4
|
L
 -17.6%
H
13.5
17.7
|
L
 -28.6%
H
13.5
21.1
|
L
 48.3%
H
7.1
24
|
L
 -53.5%
H
7.1
34.7
|
L
 -73.1%
H
7.1
60.1
|
| MEI Pharma Inc |
|
34.0
|
1
|
L
 1.0%
H
1.0
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 20.5%
H
0.8
1.0
|
L
 -15.3%
H
0.7
1.3
|
L
 -83.1%
H
0.7
8.3
|
L
 -86.5%
H
0.7
9
|
L
 -98.1%
H
0.7
71
|
L
 -96.4%
H
0.7
102.8
|
| Macrogenics Inc |
|
281.6
|
4.4
|
L
 -1.3%
H
4.4
4.6
|
L
 2.3%
H
4
4.6
|
L
 7.3%
H
4
5.1
|
L
 28.0%
H
2.9
5.1
|
L
 199.3%
H
1.3
5.1
|
L
 -12.3%
H
1.0
21.9
|
L
 -82.2%
H
1.0
28.1
|
L
 -83.6%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
7.2
|
0.4
|
L
 2.4%
H
0.4
0.5
|
L
 16.7%
H
0.4
0.5
|
L
 31.3%
H
0.3
0.5
|
L
 -4.6%
H
0.3
0.6
|
L
 -74.7%
H
0.2
2.8
|
L
 -73.1%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Mirum Pharma Inc |
|
7,137.9
|
117.1
|
L
 -1.5%
H
117.0
120.5
|
L
 -4.2%
H
113
121.8
|
L
 9.3%
H
105.2
130
|
L
 19.5%
H
88.3
130
|
L
 125.4%
H
50.3
130
|
L
 341.7%
H
23.1
130
|
L
 637.6%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
146.9
|
1.2
|
L
H
1.2
1.2
|
L
 -7.8%
H
1.2
1.3
|
L
 -9.2%
H
1.2
1.4
|
L
 -43.8%
H
1.2
2.1
|
L
 -25.3%
H
1
3.1
|
L
 -64.8%
H
0.6
3.6
|
L
 -77.7%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,622.8
|
19.4
|
L
 -1.3%
H
19.4
20.3
|
L
 -4.6%
H
18.7
20.9
|
L
 1.1%
H
18.5
23.3
|
L
 5.9%
H
15.8
23.3
|
L
 -63.4%
H
6.0
62.8
|
L
 -66.9%
H
6.0
65.0
|
L
 91.3%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,248.2
|
4.0
|
L
 0.3%
H
4
4.1
|
L
 -1.2%
H
3.9
4.2
|
L
 2.5%
H
3.8
4.6
|
L
 42.3%
H
2.6
4.6
|
L
 7.5%
H
2.2
6.5
|
L
 -8.6%
H
2.2
7.6
|
L
 -7.3%
H
2.2
7.6
|
L
 -17.4%
H
0.7
7.6
|
| Mind Medicine Inc |
|
5,742.5
|
43.3
|
L
 -2.3%
H
43.3
45.3
|
L
 -8.1%
H
43.0
48.5
|
L
 76.7%
H
35.1
49.2
|
L
 90.7%
H
19.3
49.2
|
L
 387.2%
H
8.0
49.2
|
L
 797.5%
H
2.4
49.2
|
L
 -9.0%
H
2.1
49.2
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
66.4
|
1.4
|
L
H
1.4
1.4
|
L
 -2.9%
H
1.3
1.4
|
L
 2.3%
H
1.3
1.6
|
L
 -7.5%
H
1.2
1.6
|
L
 9.8%
H
1.2
2.0
|
L
 -46%
H
1.1
2.6
|
L
 -64.4%
H
1.1
4.7
|
L
 -79.8%
H
1.1
14.5
|
| TNF Pharma Inc |
|
26.7
|
3.4
|
L
 -1.2%
H
3.4
3.5
|
L
 -5.8%
H
3.2
3.7
|
L
 -15.4%
H
3.2
4.2
|
L
 -10.3%
H
3.2
5.5
|
L
 -61.4%
H
2.5
17.4
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,587.8
|
30.7
|
L
 -3.1%
H
30.7
32.2
|
L
 -13.0%
H
30.7
35.0
|
L
 2.9%
H
29.7
37.4
|
L
 -11.5%
H
27.9
42.2
|
L
 38.2%
H
21.1
42.2
|
L
 156.4%
H
5.6
42.2
|
L
 216.1%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Minerva Neurosciences Inc |
|
196.1
|
4.2
|
L
 -1.4%
H
4.1
4.3
|
L
 -10.8%
H
3.9
4.7
|
L
 -5.8%
H
3.9
5.8
|
L
 -37.4%
H
3.9
7.6
|
L
 111.6%
H
1.8
12.5
|
L
 -54.6%
H
1.2
13.5
|
L
 -73.3%
H
1.2
17.0
|
L
 -94.9%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,221.4
|
65.8
|
L
 -3.7%
H
65.4
68.5
|
L
 -6.6%
H
64.5
70.0
|
L
 7.8%
H
61.3
77.2
|
L
 -22.5%
H
54.1
109
|
L
 163.6%
H
21.0
109
|
L
 675.4%
H
6.2
109
|
L
 -73.1%
H
6.2
290.6
|
L
 -70.7%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
19.7
|
3.7
|
L
 -10.8%
H
3.7
4.2
|
L
 -12.9%
H
3.7
4.3
|
L
 10.3%
H
3.2
4.6
|
L
 37.2%
H
2.6
5.1
|
L
 -83.6%
H
1.8
28.0
|
L
 -99.0%
H
1.2
482
|
L
 -99.7%
H
1.2
1250
|
L
H
1.2
2940
|
| NeuroSense Therapeutics Ltd |
|
24.9
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -5.5%
H
0.7
0.7
|
L
 -13.8%
H
0.7
1.0
|
L
 -2.8%
H
0.7
1.0
|
L
 -66.2%
H
0.6
2.1
|
L
 -50.7%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
185.3
|
4.3
|
L
 1.4%
H
4.3
4.4
|
L
 3.3%
H
4.0
4.6
|
L
 9.1%
H
3.1
4.6
|
L
 69.8%
H
2.6
5.1
|
L
 47.3%
H
1.6
5.1
|
L
 5.9%
H
1.1
54
|
L
 -96.5%
H
1.1
262.4
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
604.7
|
19.2
|
L
 0.2%
H
19.1
19.5
|
L
 4.5%
H
18.0
20.0
|
L
 38.8%
H
13.0
29.3
|
L
 115.5%
H
8.3
29.3
|
L
 145.9%
H
5.6
29.3
|
L
 32.4%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
24.1
|
5.9
|
L
 -1.2%
H
5.5
6.1
|
L
 200.5%
H
1.7
9.9
|
L
 193.1%
H
1.6
9.9
|
L
 -42.6%
H
1.6
13.3
|
L
 18.6%
H
1.6
15.7
|
L
 -72.0%
H
1.6
30.8
|
L
 -93.1%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,802.4
|
35.5
|
L
 -6.1%
H
35.3
39.2
|
L
 -11.4%
H
35.3
42.3
|
L
 -2.2%
H
33.1
42.9
|
L
 5.0%
H
30.2
57.1
|
L
 569.6%
H
4.9
57.1
|
L
 402.0%
H
2.8
57.1
|
L
 142.1%
H
1.8
57.1
|
L
H
1.8
57.1
|
| Ocugen Inc |
|
443.5
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -10.9%
H
1.3
1.5
|
L
 5.7%
H
1.3
1.7
|
L
 -34.2%
H
1.2
1.9
|
L
 28.4%
H
0.9
2.7
|
L
 118.3%
H
0.3
2.7
|
L
 -82.6%
H
0.3
17.7
|
L
 -98.8%
H
0.2
268.2
|
| Ocular Therapeutix Inc |
|
1,911.5
|
8.7
|
L
 -2.7%
H
8.6
9.2
|
L
 -14.4%
H
8.6
10.2
|
L
 -7.4%
H
8.6
10.9
|
L
 -11.1%
H
7.9
10.9
|
L
 -23.0%
H
6.2
16.4
|
L
 86.5%
H
2
16.4
|
L
 -28.4%
H
2
16.4
|
L
 80%
H
2
24.3
|
| Opus Genetics Inc |
|
256.0
|
3.1
|
L
 -5.2%
H
3.1
3.4
|
L
 -20.9%
H
3.1
3.9
|
L
 -23.8%
H
3.1
4.4
|
L
 -46.1%
H
3.1
5.7
|
L
 174.3%
H
1.0
5.8
|
L
 -24.0%
H
0.7
5.8
|
L
 -19.3%
H
0.7
6.6
|
L
 -97.5%
H
0.7
340.8
|
| Olema Pharma Inc |
|
993.1
|
11.4
|
L
 -0.9%
H
11.3
11.6
|
L
 -4.5%
H
10.8
12.2
|
L
 19.6%
H
9.5
13.1
|
L
 -32.4%
H
9.1
17.5
|
L
 157.8%
H
4.4
36.3
|
L
 24.4%
H
2.9
36.3
|
L
 -53.9%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
694.1
|
9.6
|
L
 -1.0%
H
9.4
9.8
|
L
 -6.7%
H
9.1
10.7
|
L
 -6.7%
H
7.4
10.8
|
L
 -28.7%
H
6.7
15.3
|
L
 185.4%
H
3.4
17.7
|
L
 68.5%
H
0.9
17.7
|
L
 -30.7%
H
0.9
17.7
|
L
 -10.4%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,104.5
|
10.7
|
L
 -0.6%
H
10.7
11
|
L
 -1.7%
H
10.3
11.3
|
L
 25.7%
H
8.7
12.1
|
L
 -0.7%
H
7.3
12.1
|
L
 -3.1%
H
7.2
14.9
|
L
 40.4%
H
3.9
16.7
|
L
 -45.1%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
166.2
|
4.1
|
L
 0.7%
H
4.0
4.1
|
L
 0.5%
H
3.9
4.3
|
L
 4.6%
H
3.8
5.2
|
L
 4.6%
H
3.6
5.2
|
L
 91.5%
H
2.0
5.2
|
L
 22.3%
H
1.7
5.2
|
L
 -67.2%
H
1.7
31.5
|
L
 -50.8%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
211.0
|
1.4
|
L
 2.2%
H
1.4
1.5
|
L
 -9.6%
H
1.3
1.8
|
L
 -10.1%
H
1.3
1.9
|
L
 358.1%
H
0.2
1.9
|
L
 -34.9%
H
0.2
3.0
|
L
 -99.8%
H
0.2
740.0
|
L
 -99.8%
H
0.2
1308
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
438.6
|
2.4
|
L
 -3.7%
H
2.4
2.5
|
L
 -6.8%
H
2.4
2.5
|
L
 3.5%
H
2.2
2.8
|
L
 -19.2%
H
2.2
3.0
|
L
 327.3%
H
0.5
3.1
|
L
 -32.1%
H
0.2
4.1
|
L
 -36.1%
H
0.2
4.2
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,340.7
|
33.1
|
L
 -0.8%
H
32.4
34.0
|
L
 3.1%
H
30.6
35.0
|
L
 3.8%
H
30.5
35.0
|
L
 -42.1%
H
28.3
58.7
|
L
 12.4%
H
25.6
60.1
|
L
 127.5%
H
9.4
60.1
|
L
 33.3%
H
9.4
60.1
|
L
 63.0%
H
9.4
60.1
|
| Palisade Bio Inc |
|
331.9
|
1.9
|
L
 -3.1%
H
1.9
2
|
L
 -2.6%
H
1.8
2.1
|
L
 2.1%
H
1.8
2.3
|
L
 -20.4%
H
1.6
2.9
|
L
 154.7%
H
0.5
2.9
|
L
 -94.1%
H
0.4
36.6
|
L
 -99.9%
H
0.4
3045
|
L
 -100.0%
H
0.4
594000
|
| Puma biotech Inc |
|
425.0
|
8.4
|
L
 -2.1%
H
8.3
8.5
|
L
 4.4%
H
7.7
8.7
|
L
 10.5%
H
7.6
8.7
|
L
 11.8%
H
6.6
8.7
|
L
 145.6%
H
3.0
8.7
|
L
 150%
H
2.1
8.7
|
L
 4.9%
H
1.6
8.7
|
L
 -73.2%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,011.2
|
25.7
|
L
 0.4%
H
25.5
26.1
|
L
 0.9%
H
24.6
26.1
|
L
 15.1%
H
22
26.7
|
L
 4.0%
H
21.9
27.1
|
L
 19.0%
H
18.8
27.6
|
L
 -30.1%
H
11.2
40.2
|
L
 -54.2%
H
11.2
82.2
|
L
 -28.0%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.4
|
2.3
|
L
 -0.4%
H
2.2
2.3
|
L
 6.5%
H
2.1
2.5
|
L
 8.5%
H
1.7
2.5
|
L
 -25.8%
H
1.7
3.5
|
L
 -56.8%
H
1.7
14.3
|
L
 -99.0%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| PDS biotech Corp |
|
39.7
|
0.7
|
L
 -4.1%
H
0.7
0.7
|
L
 -7.8%
H
0.7
0.8
|
L
 -26.0%
H
0.7
1.0
|
L
 -45.8%
H
0.7
1.6
|
L
 -38.3%
H
0.5
1.6
|
L
 -88.0%
H
0.5
6.9
|
L
 -92.6%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| Phathom Pharma Inc |
|
854.2
|
10.7
|
L
 -2.1%
H
10.7
11.2
|
L
 -15.1%
H
10.7
12.6
|
L
 -1.6%
H
10.0
12.6
|
L
 -18.8%
H
8.8
13.7
|
L
 34.7%
H
7.6
18.3
|
L
 -23.7%
H
2.2
19.7
|
L
 -67.5%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Praxis Precision Medicines Inc |
|
8,640.2
|
309.9
|
L
 -1.4%
H
308.4
325.7
|
L
 -4.6%
H
299.2
330.2
|
L
 9.8%
H
285
354.2
|
L
 -9.5%
H
238.8
366.5
|
L
 475.5%
H
37.2
366.5
|
L
 1696.6%
H
12.8
366.5
|
L
 17.9%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.7
|
1.2
|
L
 0.8%
H
1.2
1.2
|
L
 -11.1%
H
1.2
1.3
|
L
 -27.3%
H
1.2
2.3
|
L
 -56.0%
H
1.2
5.4
|
L
 -17.2%
H
0.6
5.4
|
L
 -97.2%
H
0.2
68.2
|
L
 -99.3%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
245.6
|
1.7
|
L
 2.4%
H
1.7
1.8
|
L
 0.6%
H
1.6
1.9
|
L
 -7.9%
H
1.4
2.0
|
L
 -12.6%
H
1.4
2
|
L
 -23.0%
H
1.3
3.1
|
L
 0.6%
H
1.1
4.6
|
L
 -68.1%
H
0.5
9.1
|
L
 -63.3%
H
0.5
24
|
| Plus Therapeutics Inc |
|
25.7
|
3.7
|
L
 -0.3%
H
3.7
3.8
|
L
 -6.8%
H
3.6
4.4
|
L
 -11.2%
H
3.6
4.5
|
L
 -41.6%
H
3.6
8
|
L
 -59.9%
H
2.9
23.4
|
L
 -93.1%
H
2.9
80.3
|
L
 -99.5%
H
2.9
975
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
6,449.3
|
77.8
|
L
 -1.1%
H
77.6
79.7
|
L
 -8.4%
H
76.6
83.7
|
L
 -1.6%
H
76.6
90.9
|
L
 7.4%
H
63.2
90.9
|
L
 63.2%
H
43.2
90.9
|
L
 94.3%
H
17.5
90.9
|
L
 85.6%
H
17.5
90.9
|
L
 1033.4%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
8,945.7
|
139.1
|
L
 -1.3%
H
139
143.3
|
L
 5.8%
H
125.3
143.3
|
L
 23.3%
H
113.2
143.3
|
L
 31.3%
H
92.8
143.3
|
L
 150.7%
H
50.5
143.3
|
L
 597.6%
H
13.7
143.3
|
L
 197.7%
H
6.9
143.3
|
L
H
4.5
143.3
|
| Pulmatrix Inc |
|
5.9
|
1.6
|
L
 -4.1%
H
1.6
1.7
|
L
 -5.8%
H
1.6
1.8
|
L
 11.0%
H
1.4
1.9
|
L
 28.6%
H
1.2
1.9
|
L
 -73.9%
H
1.2
6.3
|
L
 -39.1%
H
1.2
10.4
|
L
 -90.9%
H
1.2
20.8
|
L
 -99.6%
H
1.2
1396
|
| Polypid Ltd |
|
101.8
|
5.3
|
L
 -1.1%
H
5.2
5.6
|
L
 1.5%
H
5.0
5.7
|
L
 12.0%
H
4.5
5.7
|
L
 12.0%
H
4.2
5.7
|
L
 46.7%
H
3.1
5.7
|
L
 -49.9%
H
2.3
12
|
L
 -97.5%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
144.5
|
2.3
|
L
 -3.4%
H
2.3
2.4
|
L
 -14.6%
H
2.2
2.7
|
L
 12.3%
H
2.0
3.4
|
L
 37.4%
H
1.5
3.4
|
L
 101.8%
H
1.0
5.6
|
L
 -13.0%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
926.6
|
13.1
|
L
 -2.6%
H
13.1
13.2
|
L
 -5.3%
H
12.9
14.0
|
L
 1.9%
H
12.7
14.8
|
L
 -24.3%
H
11.8
17.9
|
L
 28%
H
9.5
21.3
|
L
 10.9%
H
6.7
21.3
|
L
 21.3%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
1.4
|
1.5
|
L
 -0.7%
H
1.5
1.5
|
L
 -6.4%
H
1.4
1.6
|
L
 -14.1%
H
1.4
1.9
|
L
 -70.0%
H
1.4
5
|
L
 -94.4%
H
1.4
29
|
L
 -100.0%
H
1.4
7200
|
L
 -100.0%
H
1.4
23280
|
L
 -100.0%
H
1.4
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
112.2
|
0.3
|
L
H
0.3
0.3
|
L
 -17.7%
H
0.3
0.3
|
L
 -22.2%
H
0.3
0.5
|
L
 -12.5%
H
0.3
0.5
|
L
 -97.5%
H
0.3
11.8
|
L
 -93.3%
H
0.3
17.2
|
L
 -98.6%
H
0.3
22.5
|
L
H
0.3
110
|
| Quoin Pharma Ltd (ADR) |
|
8.3
|
4.1
|
L
 -2.6%
H
4.1
4.2
|
L
 -7.2%
H
4.1
4.5
|
L
 -11.2%
H
3.3
5.1
|
L
 -36.1%
H
3.3
6.7
|
L
 -51.3%
H
3.3
41.8
|
L
 -99.9%
H
3.3
8400
|
L
 -100.0%
H
3.3
3003840
|
L
H
3.3
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
2,880.8
|
29.3
|
L
 -0.1%
H
29.2
30.0
|
L
 -13.5%
H
28.9
33.6
|
L
 6.6%
H
27.5
36.6
|
L
 17.9%
H
21.3
36.6
|
L
 11.2%
H
18.3
39.9
|
L
 -32.9%
H
18.3
60.4
|
L
 -65.3%
H
18.3
104.4
|
L
 -42.1%
H
18.3
179.7
|
| Regeneron Pharma |
|
70,870.1
|
676.0
|
L
 -0.1%
H
669.9
679.1
|
L
 1.7%
H
648.7
691.1
|
L
 10.8%
H
594.9
691.1
|
L
 -9.9%
H
591.5
767.2
|
L
 24.6%
H
541
821.1
|
L
 -6.0%
H
476.5
1211.2
|
L
 15.5%
H
476.5
1211.2
|
L
 79.2%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
2,457.6
|
5.0
|
L
 -1%
H
4.9
5.1
|
L
 -15.5%
H
4.5
6.0
|
L
 -58.6%
H
4.5
14.7
|
L
 -82.7%
H
4.5
32
|
L
 -65.7%
H
4.5
69
|
L
 771.9%
H
0.1
83.6
|
L
 1888%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,219.2
|
145.7
|
L
 -1.1%
H
145.7
148.3
|
L
 1.0%
H
141.6
150.9
|
L
 10.4%
H
124.9
150.9
|
L
 11.1%
H
101.0
150.9
|
L
 25.3%
H
101.0
175.8
|
L
 -8.1%
H
101.0
211.1
|
L
 -26.9%
H
101.0
327.3
|
L
 459.1%
H
26.2
327.3
|
| Regenxbio Inc |
|
559.1
|
10.4
|
L
 4.7%
H
10.0
10.7
|
L
 -25.8%
H
8.4
13.6
|
L
 32.7%
H
7.8
15.9
|
L
 9.1%
H
5.5
15.9
|
L
 26.8%
H
5.5
16.2
|
L
 -43.5%
H
5.0
28.8
|
L
 -70.9%
H
5.0
46.5
|
L
 41.4%
H
5.0
85.1
|
| Rigel Pharma |
|
736.9
|
39.8
|
L
 -1.8%
H
39.5
40.5
|
L
 -6.4%
H
39.5
43.3
|
L
 21.0%
H
33.6
44.0
|
L
 22.8%
H
25.5
44.0
|
L
 111.9%
H
18.8
52.2
|
L
 2894.7%
H
0.7
52.2
|
L
 881.0%
H
0.6
52.2
|
L
 1686.1%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
542.8
|
5.2
|
L
 -1.3%
H
5.2
5.5
|
L
 -19.3%
H
5.2
6.6
|
L
 -23.2%
H
5.2
7.1
|
L
 -30.9%
H
5.2
8
|
L
 791.4%
H
0.6
8
|
L
 88%
H
0.2
8
|
L
 -83.0%
H
0.2
38.7
|
L
 -40.2%
H
0.2
54
|
| RenovoRx Inc |
|
38.8
|
0.9
|
L
H
0.9
0.9
|
L
 -7.5%
H
0.8
0.9
|
L
 -6.5%
H
0.8
1
|
L
 -14%
H
0.8
1.0
|
L
 -33.9%
H
0.7
1.5
|
L
 -58.7%
H
0.6
2.4
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
24,685.4
|
34.3
|
L
 -0.6%
H
34.3
35.1
|
L
 -4.6%
H
33.6
35.6
|
L
 9.2%
H
30.7
37
|
L
 15.1%
H
27.1
37
|
L
 200%
H
10.9
37
|
L
 197.4%
H
8.2
37
|
L
 246.0%
H
2.5
37
|
L
H
2.5
37
|
| Royalty Pharma PLC (Class A) |
|
25,873.9
|
58.4
|
L
 0.3%
H
58.3
59.0
|
L
 3.4%
H
55.0
59.4
|
L
 10.2%
H
52.9
59.4
|
L
 16.7%
H
48.9
59.4
|
L
 64.0%
H
34.1
59.4
|
L
 87.9%
H
24.1
59.4
|
L
 46.5%
H
24.1
59.4
|
L
H
24.1
59.4
|
| Rhythm Pharma Inc |
|
7,225.0
|
105.3
|
L
 -1.2%
H
104.9
107.5
|
L
 -2.8%
H
104.2
110.7
|
L
 8.8%
H
97.4
115.9
|
L
 18.8%
H
79.4
115.9
|
L
 18.1%
H
74.5
122.2
|
L
 501.5%
H
17.1
122.2
|
L
 460.6%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
424.6
|
4.4
|
L
 -4.3%
H
4.4
4.7
|
L
 -7.2%
H
4.1
4.9
|
L
 -12.2%
H
4.1
5.4
|
L
 27.5%
H
2.8
5.4
|
L
 -18.2%
H
1.1
11.5
|
L
 119.4%
H
0.7
11.5
|
L
 -56.1%
H
0.7
11.8
|
L
 -91.3%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.4
|
0.7
|
L
 4.3%
H
0.7
0.7
|
L
 4.3%
H
0.6
0.8
|
L
 -9.9%
H
0.6
0.9
|
L
 -8.8%
H
0.6
1.1
|
L
 -60.8%
H
0.6
3.3
|
L
 -98.4%
H
0.6
82
|
L
 -100.0%
H
0.6
11180
|
L
 -100.0%
H
0.6
16540
|
| Sunshine Biopharma Inc |
|
3.8
|
1.8
|
L
 -1.1%
H
1.8
1.9
|
L
 -14.8%
H
1.8
2.1
|
L
 -16.4%
H
1.8
2.3
|
L
 -82.7%
H
1.8
23.2
|
L
 -88.6%
H
1.8
24.3
|
L
 -100.0%
H
1.8
12900
|
L
 -100.0%
H
1.8
596000
|
L
 -100.0%
H
1.8
45037037.0
|
| Scynexis Inc |
|
39.7
|
4
|
L
 -6.3%
H
3.9
4.3
|
L
 -8.7%
H
3.9
5.1
|
L
 -1.2%
H
3.7
5.1
|
L
 -55.0%
H
3.7
9.0
|
L
 -31.0%
H
3.7
10.5
|
L
 -82.2%
H
3.7
31.0
|
L
 -92.6%
H
3.7
64.8
|
L
 -97.5%
H
3.7
440.8
|
| Shuttle Pharma Holdings Inc |
|
1.8
|
3.1
|
L
 -3.5%
H
3
3.2
|
L
 4.5%
H
2.7
5.1
|
L
 -11.9%
H
2.7
6.2
|
L
 199.0%
H
0.4
6.2
|
L
 -20.0%
H
0.4
6.2
|
L
 -98.5%
H
0.4
206
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
246.7
|
3.4
|
L
H
3.4
3.5
|
L
 -4.2%
H
3.4
3.7
|
L
 -20.4%
H
3.4
4.4
|
L
 -27.7%
H
3.4
4.9
|
L
 -48.0%
H
3.4
9.6
|
L
 -31.1%
H
3.4
12.8
|
L
 -42.0%
H
3.4
27.0
|
L
 69.5%
H
1.9
27.0
|
| SILO Pharma Inc |
|
5.2
|
4.6
|
L
 -5.1%
H
4.6
4.8
|
L
 -19.1%
H
4.3
5.7
|
L
 -24.7%
H
4.3
8.0
|
L
 786.5%
H
0.3
8.0
|
L
 631.8%
H
0.2
8.0
|
L
 122.7%
H
0.2
8.0
|
L
 -45.9%
H
0.2
496
|
L
 -90.8%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
261.8
|
80.1
|
L
 -3.7%
H
79.7
84.5
|
L
 8.3%
H
72.3
86.9
|
L
 7.6%
H
70.4
86.9
|
L
 8.4%
H
62.5
86.9
|
L
 885.2%
H
8.0
98.0
|
L
 2269.8%
H
0.3
98.0
|
L
 566.9%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
2,377.3
|
12.1
|
L
 -8.3%
H
11.9
13.6
|
L
 -5.3%
H
11.4
13.7
|
L
 50.2%
H
8.3
15.9
|
L
 131.6%
H
4.2
15.9
|
L
 583.1%
H
1.4
15.9
|
L
 590.9%
H
0.5
15.9
|
L
 39.9%
H
0.5
15.9
|
L
 -99.9%
H
0.5
16764
|
| Soligenix Inc |
|
5.2
|
0.4
|
L
 -2.8%
H
0.4
0.4
|
L
 -2.8%
H
0.4
0.4
|
L
 -12.5%
H
0.4
0.4
|
L
 -72%
H
0.3
1.4
|
L
 -74.3%
H
0.3
6.2
|
L
 -96.8%
H
0.3
85.3
|
L
 -99.9%
H
0.3
295.2
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
5.7
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 4.4%
H
1.1
1.3
|
L
 -47.8%
H
0.9
2.9
|
L
 -66.6%
H
0.9
6.9
|
L
 3.4%
H
0.1
6.9
|
L
 -79.7%
H
0.1
13.4
|
L
 -97.0%
H
0.1
74.2
|
| SciSparc Ltd |
|
2.8
|
4.9
|
L
 -1.6%
H
4.8
5.2
|
L
 4.7%
H
4.2
5.4
|
L
 -33.6%
H
4.2
7.4
|
L
 11.3%
H
4
15.8
|
L
 -92.8%
H
3.0
80.1
|
L
 -99.8%
H
3.0
2997.5
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| ARS Pharma Inc |
|
655.4
|
6.6
|
L
 -5.7%
H
6.5
7.1
|
L
 -16.9%
H
6.5
7.9
|
L
 -31.6%
H
6.5
10.9
|
L
 -19.3%
H
6.5
10.9
|
L
 -63.2%
H
6.5
18.6
|
L
 -9.7%
H
2.6
18.9
|
L
 -78.8%
H
2.6
35.6
|
L
H
2.6
63.4
|
| Sarepta Therapeutics Inc |
|
1,805.4
|
17.1
|
L
 -0.7%
H
17.0
17.7
|
L
 -9.8%
H
16.7
19.4
|
L
 -2.5%
H
15.8
20.9
|
L
 -20.7%
H
14.7
23.5
|
L
 21.5%
H
10.4
25.3
|
L
 -83.9%
H
10.4
173.3
|
L
 -74.1%
H
10.4
173.3
|
L
 -19.1%
H
10.4
181.8
|
| Sutro Biopharma Inc |
|
374.5
|
22.6
|
L
 -4.1%
H
22.5
24.1
|
L
 -24.0%
H
22.5
29.9
|
L
 -23.7%
H
22.5
34.1
|
L
 -28.4%
H
22.5
43.9
|
L
 197.4%
H
7.2
43.9
|
L
 -53.9%
H
5.2
61.3
|
L
 -86.7%
H
5.2
237
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,806.2
|
48.4
|
L
 0.7%
H
47.9
48.8
|
L
 -0.2%
H
46.1
49.1
|
L
 9.0%
H
44.1
51.4
|
L
 -5.9%
H
42.5
53.0
|
L
 49.5%
H
32.2
59.7
|
L
 59.5%
H
22
59.7
|
L
 77.4%
H
22
59.7
|
L
 130.8%
H
13.1
61.3
|
| Savara Inc |
|
1,127.1
|
5.5
|
L
 -0.4%
H
5.5
5.7
|
L
 -8.8%
H
5.4
5.9
|
L
H
5.4
6.5
|
L
 -4.8%
H
4.7
6.5
|
L
 143.4%
H
2.3
7
|
L
 69.8%
H
1.9
7
|
L
 310.4%
H
1.0
7
|
L
 -81.8%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
95.2
|
2.5
|
L
 1.6%
H
2.5
2.5
|
L
 -2.4%
H
2.2
2.7
|
L
 11.7%
H
1.9
2.9
|
L
 23.9%
H
1.4
2.9
|
L
 50.9%
H
0.0
7.0
|
L
 -50.2%
H
0.0
9.4
|
L
 -94%
H
0.0
57
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
105,397.7
|
44.0
|
L
 -1.4%
H
43.8
44.1
|
L
 1.2%
H
43.0
44.9
|
L
 3.9%
H
40.9
44.9
|
L
 -8.4%
H
40.9
48.6
|
L
 -8.9%
H
40.9
52.7
|
L
 -18.1%
H
40.9
60.1
|
L
 -13.9%
H
36.9
60.1
|
L
 6.9%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
229.3
|
4.1
|
L
 -0.5%
H
4.0
4.2
|
L
 -5.6%
H
4.0
4.3
|
L
 2.5%
H
3.8
4.5
|
L
 -25%
H
3.6
5.7
|
L
 32.5%
H
3.0
7.8
|
L
 50.6%
H
1.0
10.5
|
L
 -50.8%
H
1.0
10.5
|
L
 -98.8%
H
1.0
458
|
| Tarsus Pharma Inc |
|
2,507.9
|
57.5
|
L
 -4.0%
H
57.5
60.4
|
L
 -1.1%
H
53.9
60.4
|
L
 -9.0%
H
53.9
72.5
|
L
 -14.5%
H
53.9
72.5
|
L
 32.9%
H
38.5
85.3
|
L
 185.8%
H
12.7
85.3
|
L
 124.4%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
878.0
|
16.9
|
L
 0.1%
H
16.9
17.0
|
L
 0.1%
H
16.9
17
|
L
 2.2%
H
16.4
17.7
|
L
 -1.7%
H
15.5
17.7
|
L
 50.6%
H
10.8
21.0
|
L
 75.4%
H
7.4
21.0
|
L
 26.7%
H
6.1
21.0
|
L
 -23.9%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
403.2
|
15.2
|
L
 -4.1%
H
15.2
16.0
|
L
 -13.4%
H
14.6
17.2
|
L
 26.7%
H
11.9
19.4
|
L
 5.2%
H
10.3
19.4
|
L
 155.0%
H
5.8
19.4
|
L
 -45.2%
H
2.8
61.2
|
L
 -99.5%
H
2.8
3135.0
|
L
 -100.0%
H
2.8
85120
|
| TG Therapeutics Inc |
|
8,398.2
|
54.9
|
L
 0.0%
H
54.7
56.3
|
L
 -4.0%
H
53.4
56.9
|
L
 3.1%
H
51.2
59.3
|
L
 55.3%
H
33.2
59.3
|
L
 44.7%
H
25.3
59.3
|
L
 158.3%
H
6.5
59.3
|
L
 48.8%
H
3.5
59.3
|
L
 874.4%
H
3.3
59.3
|
| Alpha Teknova Inc |
|
279.9
|
5.2
|
L
 -3.7%
H
5.2
5.5
|
L
 -2.6%
H
5.0
5.7
|
L
 -0.4%
H
4.7
6.1
|
L
 78.2%
H
2.8
6.1
|
L
 22.3%
H
1.9
6.7
|
L
 38.1%
H
1.2
10.4
|
L
 -71.1%
H
1.2
28.6
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
128.5
|
1.0
|
L
 -5.6%
H
1.0
1.1
|
L
 -17.9%
H
1.0
1.5
|
L
 -12.9%
H
1.0
1.5
|
L
 -18.6%
H
1.0
1.9
|
L
 -34.8%
H
1.0
2.6
|
L
 50.7%
H
0.4
2.6
|
L
 -44.5%
H
0.4
2.6
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
188.1
|
11.8
|
L
 -5.1%
H
11.8
12.4
|
L
 -5.8%
H
10.9
12.8
|
L
 -1.8%
H
10.9
13.6
|
L
 -15.6%
H
10.0
15.9
|
L
 -74.9%
H
10.0
70.0
|
L
 -99.8%
H
0.2
5824
|
L
 -100.0%
H
0.2
697600
|
L
 -100.0%
H
0.2
1792000000
|
| Tenaya Therapeutics Inc |
|
169.3
|
0.8
|
L
 -4.9%
H
0.8
0.8
|
L
 -10.3%
H
0.8
0.9
|
L
 6.9%
H
0.7
1.0
|
L
H
0.7
1.2
|
L
 -11.4%
H
0.5
2.4
|
L
 -85.5%
H
0.4
7.0
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
15.5
|
1.0
|
L
H
1.0
1.0
|
L
H
0.9
1.1
|
L
 -21.1%
H
0.9
1.3
|
L
 -50.5%
H
0.9
2.2
|
L
 -84.6%
H
0.9
12.2
|
L
 -11.8%
H
0.2
12.2
|
L
 -95.1%
H
0.2
21.2
|
L
 -99.9%
H
0.2
2020.5
|
| Travere Therapeutics Inc |
|
5,163.9
|
55.5
|
L
 -2.1%
H
55.3
58.1
|
L
 -1.9%
H
53
58.1
|
L
 0.7%
H
53
60.1
|
L
 36.2%
H
38.4
60.1
|
L
 244.7%
H
15.0
60.1
|
L
 259.4%
H
5.1
60.1
|
L
 306.5%
H
5.1
60.1
|
L
 217.3%
H
5.1
60.1
|
| TherapeuticsMD Inc |
|
24.3
|
2.1
|
L
 1.9%
H
2.1
2.1
|
L
 5%
H
1.9
2.1
|
L
 7.7%
H
1.9
2.4
|
L
 1.5%
H
1.8
2.4
|
L
 82.6%
H
1.0
3.0
|
L
 -48.1%
H
0.7
4.4
|
L
 -95.7%
H
0.7
54
|
L
 -99.5%
H
0.7
414.8
|
| Universe Pharma INC |
|
2.8
|
4.4
|
L
 -1.8%
H
4.0
4.5
|
L
 -17.1%
H
4.0
5.6
|
L
 48.1%
H
2.6
18.0
|
L
 29.3%
H
2.5
18.0
|
L
 33.6%
H
2
18.0
|
L
 -20.7%
H
0.1
64.8
|
L
 -88.8%
H
0.1
75
|
L
H
0.1
179.9
|
| Vericel Corp |
|
2,354.2
|
46.1
|
L
 -1.2%
H
45.9
46.9
|
L
 -1.9%
H
44.6
48.8
|
L
 15.0%
H
39.3
48.8
|
L
 29.2%
H
31.9
48.8
|
L
 30.5%
H
29.0
48.8
|
L
 17.5%
H
29.0
63
|
L
 -7.6%
H
17.3
63
|
L
 2054.2%
H
2
68.9
|
| Veru Inc |
|
36.6
|
2.3
|
L
 -4.2%
H
2.3
2.4
|
L
 -18.0%
H
2.3
2.8
|
L
 -22.7%
H
2.3
3.4
|
L
 -6.6%
H
2.1
7.3
|
L
 -61.8%
H
2.1
7.3
|
L
 -82.9%
H
2.1
19.2
|
L
 -96.7%
H
2.1
245.5
|
L
 -82.0%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
45.1
|
1.3
|
L
 -2.9%
H
1.3
1.4
|
L
 -5.6%
H
1.3
1.5
|
L
 -13.6%
H
1.3
1.8
|
L
 -19.3%
H
1.3
2.0
|
L
 -72.3%
H
1.3
9.5
|
L
 -35.6%
H
0.1
29.3
|
L
 -76.7%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,307.5
|
37.1
|
L
 0.1%
H
37
38.1
|
L
 -4.5%
H
35.3
38.7
|
L
 22.1%
H
30.5
42.8
|
L
 5.4%
H
27.2
42.8
|
L
 15.9%
H
23.0
43.2
|
L
 143.8%
H
8.3
99.4
|
L
 538.6%
H
2.0
99.4
|
L
 2798.4%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
324.1
|
5.4
|
L
 -0.9%
H
5.4
5.5
|
L
 -13.6%
H
5.3
6.2
|
L
 -7.1%
H
5.3
6.6
|
L
 -25.9%
H
5.3
7.7
|
L
 12.8%
H
4.1
9.9
|
L
 -15.1%
H
3.3
9.9
|
L
 -71.0%
H
3.3
21.4
|
L
 -51.3%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
97.4
|
5.7
|
L
 1.4%
H
5.6
5.7
|
L
 -9.4%
H
5.1
6.4
|
L
 0.7%
H
5.1
7
|
L
 -10.3%
H
5.1
8.5
|
L
 591.5%
H
0.7
9.8
|
L
 -19.9%
H
0.4
11.4
|
L
 -46.2%
H
0.4
14.8
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,035.2
|
18.4
|
L
 2.2%
H
18.1
18.7
|
L
 -6.6%
H
17.5
19.7
|
L
 10.8%
H
16.9
20.9
|
L
 24.5%
H
13.2
20.9
|
L
 11.6%
H
13.2
34.3
|
L
 -15.3%
H
9.9
34.3
|
L
 8.7%
H
9.5
39
|
L
 -81.4%
H
4.7
270
|
| Vertex Pharma |
|
123,324.1
|
485.9
|
L
 0.1%
H
484.4
491.2
|
L
 0.1%
H
469.6
496.7
|
L
 7.6%
H
453.2
533.7
|
L
 10.1%
H
412.3
533.7
|
L
 5.7%
H
362.5
533.7
|
L
 35.5%
H
340.2
533.7
|
L
 143.9%
H
176.4
533.7
|
L
 455.8%
H
71.5
533.7
|
| Viatris |
|
19,948.8
|
17.1
|
L
 -0.9%
H
17.1
17.5
|
L
 5.3%
H
16.1
17.7
|
L
 11.5%
H
15.1
17.7
|
L
 16.7%
H
14.4
17.7
|
L
 92.9%
H
8.6
17.7
|
L
 64.2%
H
6.9
17.7
|
L
 26.0%
H
6.9
17.7
|
L
 -61.9%
H
6.9
50.4
|
| vTv Therapeutics Inc (Class A) |
|
128.8
|
32.7
|
L
 -0.5%
H
32.1
33.3
|
L
 -2.3%
H
30.0
34.0
|
L
 -6.7%
H
30.0
38.8
|
L
 -14.2%
H
28.8
41.4
|
L
 95.1%
H
14
44
|
L
 4443.1%
H
0.4
44
|
L
 1495.6%
H
0.4
44
|
L
 490.4%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
27.0
|
0.8
|
L
 6.6%
H
0.8
0.8
|
L
 26.6%
H
0.6
0.8
|
L
 26.6%
H
0.6
0.8
|
L
 32.8%
H
0.6
0.8
|
L
 -30.2%
H
0.3
1.6
|
L
 -82.1%
H
0.3
6.8
|
L
 -98.4%
H
0.3
55.1
|
L
H
0.3
2869.9
|
| Xenetic Biosciences Inc |
|
6.6
|
2.9
|
L
 3.2%
H
2.8
2.9
|
L
 4.7%
H
2.7
3.1
|
L
 2.5%
H
2.7
3.1
|
L
 -18.7%
H
2.7
3.5
|
L
 -21.6%
H
1.9
13.9
|
L
 -27.0%
H
1.9
13.9
|
L
 -83.4%
H
1.9
56.8
|
L
 -99.5%
H
1.9
1074
|
| Xenon Pharma Inc |
|
6,482.4
|
67.1
|
L
 -1.8%
H
67.1
68.8
|
L
 -2.7%
H
65.5
69.6
|
L
 26.7%
H
52.9
72.7
|
L
 12.3%
H
50.9
72.7
|
L
 112.3%
H
30
72.7
|
L
 71.3%
H
26.7
72.7
|
L
 275.3%
H
14.7
72.7
|
L
 758.6%
H
2.1
72.7
|
| Xilio Therapeutics Inc |
|
58.5
|
8.9
|
L
 0.2%
H
8.8
9.0
|
L
 -2.2%
H
8.6
9.3
|
L
 1.3%
H
8.5
9.9
|
L
 3.9%
H
7.4
9.9
|
L
 -12.0%
H
6.5
12.7
|
L
 -76.1%
H
6.5
41.1
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XORTX Therapeutics Inc |
|
3.6
|
2.1
|
L
 3.5%
H
2.0
2.1
|
L
 -4.6%
H
2.0
2.2
|
L
 -0.5%
H
2.0
2.3
|
L
 -8.4%
H
2.0
3.6
|
L
 -91.0%
H
1.7
35.3
|
L
 -98.6%
H
1.7
188.1
|
L
 -99.5%
H
1.7
1841.6
|
L
H
1.7
1841.6
|
| Zevra Therapeutics Inc |
|
741.3
|
12.5
|
L
 -1.8%
H
12.5
13.0
|
L
 -6.1%
H
12.4
13.3
|
L
 -2.8%
H
12.4
15.0
|
L
 17.5%
H
9.5
15.0
|
L
 3.9%
H
7.2
15.0
|
L
 153.8%
H
3.9
15.0
|
L
 16.2%
H
3.9
15.0
|
L
 -80.6%
H
1.9
134.4
|
| Zymeworks BC Inc |
|
1,770.2
|
24.1
|
L
 -0.5%
H
23.9
24.5
|
L
 -7.0%
H
23.9
25.8
|
L
 4.0%
H
21.9
27.4
|
L
 -13.5%
H
21.9
29.8
|
L
 68.8%
H
11.5
29.8
|
L
 205.7%
H
6.0
29.8
|
L
 -33.3%
H
4.1
38.6
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
462.5
|
7.5
|
L
 -4.2%
H
7.5
8.0
|
L
 1.6%
H
7.0
8.1
|
L
 12.1%
H
6.7
8.1
|
L
 15.8%
H
5.7
9.4
|
L
 -20.4%
H
4.5
11.4
|
L
 -1.7%
H
1.7
20.7
|
L
 -1.7%
H
1.7
20.7
|
L
 -1.7%
H
1.7
20.7
|
| Neumora Therapeutics Inc |
|
300.2
|
1.6
|
L
 0.6%
H
1.6
1.7
|
L
 -3.6%
H
1.6
1.7
|
L
 7.3%
H
1.4
1.8
|
L
 -24.7%
H
0.8
2.6
|
L
 -12.4%
H
0.8
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Conduit Pharma Inc |
|
2.1
|
3.3
|
L
 964.5%
H
3.1
3.5
|
L
 768.4%
H
0.3
3.5
|
L
 223.5%
H
0.3
3.5
|
L
 -4.6%
H
0.3
3.5
|
L
 -99.2%
H
0.3
450
|
L
 -100.0%
H
0.3
7500000
|
L
H
0.3
7500000
|
L
H
0.3
7500000
|
| Gyre Therapeutics Inc |
|
656.7
|
5.9
|
L
 -2.6%
H
5.9
6.2
|
L
 -9.7%
H
5.9
6.6
|
L
 -5.8%
H
5.9
7.5
|
L
 -27.3%
H
5.4
8.1
|
L
 -18.3%
H
5.4
9.4
|
L
 -21.5%
H
5.4
130.5
|
L
 -21.5%
H
5.4
130.5
|
L
 -21.5%
H
5.4
130.5
|
| Korro Bio Inc |
|
171.1
|
11.9
|
L
 -3.2%
H
11.7
12.7
|
L
 -18.5%
H
11.5
14.5
|
L
 -8.7%
H
11.5
15.6
|
L
 -17.6%
H
9.1
15.6
|
L
 -13.2%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
24.9
|
0.6
|
L
 8.9%
H
0.6
0.7
|
L
 -4.7%
H
0.6
0.7
|
L
 -7.6%
H
0.6
0.8
|
L
 3.4%
H
0.6
0.8
|
L
 -59.3%
H
0.5
2.9
|
L
 -83.2%
H
0.5
5.1
|
L
 -83.2%
H
0.5
5.1
|
L
 -83.2%
H
0.5
5.1
|
| Spyre Therapeutics Inc |
|
8,706.7
|
100.3
|
L
 0.0%
H
100.1
102.9
|
L
 2.6%
H
92.4
105.1
|
L
 13.5%
H
81.7
105.1
|
L
 37.3%
H
64.7
105.1
|
L
 515.5%
H
14.5
105.1
|
L
H
8.8
105.1
|
L
H
8.8
105.1
|
L
H
8.8
105.1
|
| Onconetix Inc |
|
2.7
|
0.7
|
L
 -5.3%
H
0.7
0.8
|
L
 -23.4%
H
0.7
0.9
|
L
 -23.4%
H
0.7
1.2
|
L
 -90.3%
H
0.7
8.4
|
L
 -99.6%
H
0.7
229.5
|
L
 -100.0%
H
0.7
202249
|
L
 -100.0%
H
0.7
15453000
|
L
 -100.0%
H
0.7
15453000
|
| Talphera Inc |
|
65.4
|
1.3
|
L
 -4.6%
H
1.3
1.3
|
L
 -13.7%
H
1.3
1.5
|
L
 15.6%
H
1.0
1.5
|
L
 57.5%
H
0.7
1.5
|
L
 207.3%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| Telomir Pharma Inc |
|
66.7
|
1.0
|
L
 -12.6%
H
0.9
1.0
|
L
 -21.1%
H
0.9
1.3
|
L
 -31.7%
H
0.9
1.4
|
L
 -33.1%
H
0.9
1.5
|
L
 -57.5%
H
0.9
2.4
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
| Skye Bioscience Inc |
|
23.2
|
0.7
|
L
 1.5%
H
0.6
0.7
|
L
 -4.4%
H
0.6
0.7
|
L
 -7.0%
H
0.6
0.8
|
L
 -16.5%
H
0.6
1.1
|
L
 -83.0%
H
0.6
5.0
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
| Alumis Inc |
|
3,622.0
|
28.4
|
L
 -0.9%
H
28.4
29.6
|
L
 0.4%
H
26.1
29.6
|
L
 21.4%
H
23.0
31.4
|
L
 13.7%
H
18.4
31.4
|
L
 753.2%
H
3.2
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
| Actuate Therapeutics Inc |
|
34.7
|
1.5
|
L
 0.7%
H
1.5
1.5
|
L
 19.8%
H
1.3
2.0
|
L
 -30.0%
H
1.2
2.3
|
L
 -37.2%
H
1.2
3.4
|
L
 -74.8%
H
1.2
9.2
|
L
H
1.2
12.0
|
L
H
1.2
12.0
|
L
H
1.2
12.0
|
| Bicara Therapeutics Inc |
|
1,822.6
|
27.7
|
L
 -0.1%
H
27.6
28.1
|
L
 -4.1%
H
26.6
28.8
|
L
 19.4%
H
23.3
31.0
|
L
 15.5%
H
18.6
31.0
|
L
 153.8%
H
9.6
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
| Gelteq Ltd |
|
6.3
|
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 13.5%
H
0.4
0.6
|
L
 -43.3%
H
0.4
1.1
|
L
 -15.7%
H
0.4
2.0
|
L
 -67.6%
H
0.4
2.0
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
| BeiGene Ltd (ADR) |
|
32,398.4
|
312.3
|
L
 0.1%
H
311.9
319.0
|
L
 4.5%
H
301.1
323.8
|
L
 15.6%
H
265.3
323.8
|
L
 -3.6%
H
254.0
323.8
|
L
 6.0%
H
254.0
385.2
|
L
 69.1%
H
172.7
385.2
|
L
 69.1%
H
172.7
385.2
|
L
 69.1%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
8.2
|
0.2
|
L
H
0.2
0.2
|
L
 -10.5%
H
0.2
0.2
|
L
 -29.2%
H
0.2
0.3
|
L
 -61.4%
H
0.2
0.5
|
L
 -89.5%
H
0.2
1.9
|
L
 -70.7%
H
0.2
3.3
|
L
 -70.7%
H
0.2
3.3
|
L
 -70.7%
H
0.2
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
1,749.1
|
18.7
|
L
H
18.5
19.3
|
L
 -6.2%
H
18.5
20.4
|
L
 9.5%
H
16.4
20.4
|
L
 -31.6%
H
16.4
26.7
|
L
 -53.6%
H
16.4
48.5
|
L
 7.8%
H
16.4
48.5
|
L
 7.8%
H
16.4
48.5
|
L
 7.8%
H
16.4
48.5
|
| Maze Therapeutics Inc |
|
1,553.5
|
28.1
|
L
 -0.2%
H
28.0
28.9
|
L
 -8.2%
H
26.4
30.6
|
L
 9.3%
H
25.2
33.5
|
L
 -0.1%
H
22.7
33.5
|
L
 57.9%
H
12.8
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
137.9
|
6.3
|
L
 7.5%
H
5.8
6.3
|
L
 -17.1%
H
5.7
7.9
|
L
 60.3%
H
3.9
7.9
|
L
 20.5%
H
3.4
7.9
|
L
 -45.8%
H
3.4
17.9
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
10.7
|
4.0
|
L
 0.5%
H
3.9
4
|
L
 -19.7%
H
3.9
5.0
|
L
 -8.7%
H
3.8
8.3
|
L
 48.9%
H
1.8
14.8
|
L
 -93.4%
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
| Jyong Biotech Ltd |
|
164.8
|
2.2
|
L
 -1.8%
H
2.2
2.4
|
L
 0.5%
H
2.2
2.4
|
L
 42.3%
H
1.5
2.4
|
L
 -9.0%
H
1.5
2.5
|
L
 -79.0%
H
1.4
67
|
L
 -78.0%
H
1.4
67
|
L
 -78.0%
H
1.4
67
|
L
 -78.0%
H
1.4
67
|
| LB Pharmaceuticals Inc |
|
881.2
|
30.7
|
L
 -2.2%
H
30.7
32.3
|
L
 -6.7%
H
29.4
33.8
|
L
 2.4%
H
29.4
35.3
|
L
 0.7%
H
26.4
35.3
|
L
 77.6%
H
13.4
35.3
|
L
 77.6%
H
13.4
35.3
|
L
 77.6%
H
13.4
35.3
|
L
 77.6%
H
13.4
35.3
|
| Black Titan Corp |
|
9.6
|
0.9
|
L
 -3.3%
H
0.9
1.0
|
L
 17.1%
H
0.8
1
|
L
 18.7%
H
0.7
1
|
L
 -39.9%
H
0.7
1.5
|
L
 -96.3%
H
0.7
23.5
|
L
 -96.3%
H
0.7
23.5
|
L
 -96.3%
H
0.7
23.5
|
L
 -96.3%
H
0.7
23.5
|
| Turn Therapeutics Inc |
|
294.9
|
9.9
|
L
 8.6%
H
9.3
10.1
|
L
 4.9%
H
8.5
10.2
|
L
 68.7%
H
5.6
11.7
|
L
 186.1%
H
3.2
11.7
|
L
 41.4%
H
2.6
26.5
|
L
 41.4%
H
2.6
26.5
|
L
 41.4%
H
2.6
26.5
|
L
 41.4%
H
2.6
26.5
|
| MapLight Therapeutics Inc |
|
1,693.2
|
37.3
|
L
 -1.4%
H
37.2
38.9
|
L
 -5.0%
H
35.3
39.3
|
L
 29.6%
H
28.0
40.4
|
L
 24.3%
H
25.2
40.4
|
L
 103.6%
H
12.2
40.4
|
L
 103.6%
H
12.2
40.4
|
L
 103.6%
H
12.2
40.4
|
L
 103.6%
H
12.2
40.4
|
| NovaBridge Biosciences ADR |
|
208.2
|
1.8
|
L
 1.1%
H
1.8
1.9
|
L
 -5.3%
H
1.7
2.0
|
L
 20%
H
1.5
2.3
|
L
 -33.3%
H
1.5
2.7
|
L
 -60.4%
H
1.5
5.2
|
L
 -60.4%
H
1.5
5.2
|
L
 -60.4%
H
1.5
5.2
|
L
 -60.4%
H
1.5
5.2
|
| Evommune Inc |
|
408.8
|
11.4
|
L
 -6.5%
H
11.2
12.4
|
L
 -14.1%
H
11.2
13.3
|
L
 -46.9%
H
11.2
25.9
|
L
 -58.7%
H
11.2
29.1
|
L
 -43.9%
H
11.2
33.2
|
L
 -43.9%
H
11.2
33.2
|
L
 -43.9%
H
11.2
33.2
|
L
 -43.9%
H
11.2
33.2
|
| Aktis Oncology Inc |
|
-
|
24.3
|
L
 -2.5%
H
24.2
25.3
|
L
 -12.9%
H
24.2
27.4
|
L
 0.8%
H
24.1
34.2
|
L
 19.9%
H
17.9
34.2
|
L
 8.4%
H
14.7
34.2
|
L
 8.4%
H
14.7
34.2
|
L
 8.4%
H
14.7
34.2
|
L
 8.4%
H
14.7
34.2
|
| Helus Pharma Inc |
|
445.0
|
7.2
|
L
 -1.0%
H
7.2
7.4
|
L
 4.5%
H
6.4
7.5
|
L
 53.8%
H
4.8
7.5
|
L
 30.6%
H
3.8
7.5
|
L
 -4.7%
H
3.8
8.6
|
L
 -4.6%
H
3.8
8.6
|
L
 -4.6%
H
3.8
8.6
|
L
 -4.6%
H
3.8
8.6
|
| NervGen Pharma Corp |
|
184.1
|
1.7
|
L
 3.6%
H
1.7
1.8
|
L
 -8.0%
H
1.6
2.1
|
L
 -21.4%
H
1.6
2.3
|
L
 -57.5%
H
1.6
4.2
|
L
 -69.9%
H
1.6
5.9
|
L
 -69.9%
H
1.6
5.9
|
L
 -69.9%
H
1.6
5.9
|
L
 -69.9%
H
1.6
5.9
|
| Veradermics Inc |
|
4,474.1
|
107.1
|
L
 -3.8%
H
106.7
115.5
|
L
 -10.5%
H
104.5
129.8
|
L
 14.1%
H
95.9
131.2
|
L
 40.4%
H
65.8
131.2
|
L
 183.7%
H
35.1
131.2
|
L
 183.7%
H
35.1
131.2
|
L
 183.7%
H
35.1
131.2
|
L
 183.7%
H
35.1
131.2
|
| Eikon Therapeutics Inc |
|
523.5
|
9.7
|
L
 -1.0%
H
9.7
10.4
|
L
 -8.6%
H
9.4
10.6
|
L
 0.6%
H
9.3
13.5
|
L
 -18.7%
H
7.9
13.5
|
L
 -35.5%
H
7.9
16.5
|
L
 -35.5%
H
7.9
16.5
|
L
 -35.5%
H
7.9
16.5
|
L
 -35.5%
H
7.9
16.5
|
| Satellos Bioscience Inc |
|
177.3
|
8.5
|
L
 -4.9%
H
8.4
8.8
|
L
 -13.1%
H
8.4
9.7
|
L
 49.0%
H
5.4
10
|
L
 -2.2%
H
5.4
10
|
L
 -24.4%
H
5.4
13.4
|
L
 -24.4%
H
5.4
13.4
|
L
 -24.4%
H
5.4
13.4
|
L
 -24.4%
H
5.4
13.4
|
| Avalyn Pharma Inc |
|
1,280.3
|
28.9
|
L
 2.1%
H
27.8
29.0
|
L
 2.9%
H
24.9
29.3
|
L
 -8.2%
H
24.9
33.3
|
L
 -2.1%
H
24.2
33.3
|
L
 -2.1%
H
24.2
33.3
|
L
 -2.1%
H
24.2
33.3
|
L
 -2.1%
H
24.2
33.3
|
L
 -2.1%
H
24.2
33.3
|
| Seaport Therapeutics Inc |
|
1,093.1
|
20.4
|
L
 -2.1%
H
20.3
22.1
|
L
 -5.4%
H
19.1
22.1
|
L
 12.4%
H
17.6
23.0
|
L
 2.9%
H
14.9
23.0
|
L
 2.9%
H
14.9
23.0
|
L
 2.9%
H
14.9
23.0
|
L
 2.9%
H
14.9
23.0
|
L
 2.9%
H
14.9
23.0
|
| Palatin Technologies Inc |
|
-
|
9.1
|
L
H
8.0
9.1
|
L
 -9.1%
H
8.0
10.2
|
L
 -22.4%
H
8.0
12.2
|
L
 -35.8%
H
8.0
14.8
|
L
 -35.8%
H
8.0
14.8
|
L
 -35.8%
H
8.0
14.8
|
L
 -35.8%
H
8.0
14.8
|
L
 -35.8%
H
8.0
14.8
|
| Parabilis Medicines Inc |
|
3,386.8
|
27.7
|
L
 -6.3%
H
27.6
30.2
|
L
 -9.4%
H
27.6
31.6
|
L
 7.1%
H
25.6
33.7
|
L
 -12.4%
H
24.5
34.5
|
L
 -12.4%
H
24.5
34.5
|
L
 -12.4%
H
24.5
34.5
|
L
 -12.4%
H
24.5
34.5
|
L
 -12.4%
H
24.5
34.5
|
| Vicore Pharma Holding AB ADR |
|
328.0
|
11.7
|
L
 -1.4%
H
11.7
11.7
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|
L
 -15.5%
H
11.1
12.9
|